

Risk factor disclosure complexity and litigation risk: Evidence from textual analysis

Ankita Marwaha
Indian School of Business
Ankita_marwaha@isb.edu

This paper has benefitted from the comments of my dissertation committee – Sanjay Kallapur, Hariom Manchiraju and Ram NV Ramanan, and also from comments by Prachi Deuskar, Ankit Jain, Saipriya Kamath, Srini Rangan, Gurvinder Sandhu, Mani Sethuraman, Shyam Sunder, Rajita Verma, Nitin Vishen, and all my colleagues at Indian School of Business. I am grateful to Allen Huang for providing me with data on the measure *Liberal Court*.

Risk factor disclosure complexity and litigation risk: Evidence from textual analysis

ABSTRACT

Risk factor disclosures were mandated as a discussion of risks faced by the firm. However, industry has criticized them as being unclear and uninformative of firm risks. A major reason cited for this is firms' defensive approach to risk factor disclosures, where providing all possible risks helps shield them from potential shareholder lawsuits. Using liberal court, an exogenous measure of litigation risk, I look at the direct impact of litigation risk on complexity of risk factor disclosures. I predict and find that when firms anticipate higher risks of shareholder litigation, their risk factor disclosure language shows more complexity. In further tests I find that this complexity is associated with more information asymmetry, thus closing the link between complex risk factor disclosures and informativeness. Overall, my results are consistent with firms using risk factor disclosures to seek safe harbor from litigation, and in the process, making the language complex and less informative.

Keywords: risk disclosure, textual analysis, litigation risk, language complexity

JEL Classification: G38, M4

1. Introduction

“I urge you—in long and short documents, in prospectuses and shareholder reports—to speak to investors in words they can understand. Tell them plainly what they need to know to make intelligent investment decisions.”

- Arthur Levitt, Chairman, SEC¹

Risk factor disclosures were mandated by the SEC in 2005 as a concise description of “most significant factors that make an investment in the registrant or offering speculative or risky” (Regulation S–K, Item 105 SEC 2019).² However, practitioners have called these disclosures incomprehensible, generic, voluminous, and “a flood of words that obscures, rather than reveals, the actual risks that a company is facing” (Berkman, 2018; EY, 2017). A litigious environment is cited as the factor that drives risk factor disclosure volume and complexity (EY & FERF, 2015). There are arguments that risk factor disclosures are driven by fears of security litigation (Berkman, 2018). There are also anecdotes that companies trying to streamline these disclosures face resistance from legal counsel (EY, 2014). Industry criticism has thus focused on litigation risk as a cause of complexity in risk factor disclosures.³ This paper examines whether litigation risk⁴ drives risk factor disclosure complexity, and whether such complexity in turn increases information asymmetry.

Most academic studies on risk factor disclosures thus far have examined the informativeness of these disclosures and found that these disclosures reflect risk-related firm characteristics,

¹ *A Plain English Handbook: How to create clear SEC disclosure documents, The Office of Investor Education and Assistance, SEC*

² <https://www.govinfo.gov/content/pkg/CFR-2012-title17-vol2/pdf/CFR-2012-title17-vol2-sec229-503.pdf>

³ E.g., When the SEC asked for comments on the risk factor disclosure requirement, there were observations that litigation liability concerns contribute to risk factor disclosure length (<https://www.sec.gov/rules/concept/2016/33-10064.pdf>), Mary Jo White in a 2013 conference address mentioned that risk factor disclosures have become more and more extensive over time due to advice from legal attorneys (<https://www.sec.gov/news/speech/spch101513mjw>), industry reports have observed that the volume and complexity is driven by concerns to prevent shareholder litigation (EY & FERF, 2015), and that these disclosures sit in the “corner of the legal department, and the corner of the financial reporting” (Berkman, 2018).

⁴ Borrowing from the Huang et al. (2019) study I define litigation risk to be the firm’s risk of losing a shareholder lawsuit on account of a non-friendly judge panel, which I refer to as liberal court.

and that they are used by the market. E.g., Filzen, (2015), Campbell et al., (2014) and Campbell et al., (2019) find association of risk factor disclosures with firms' risk-related negative outcomes, and Campbell et al., (2014), Chiu et al., (2018), and Filzen, (2015) find that market reacts to risk factor disclosures. These studies therefore argue that risk factor disclosures are informative.

Thus, there is considerable difference in industry and academic perceptions of risk factor disclosures, something also noted by SEC.⁵ Beatty et al., 2019 try to reconcile this difference by testing and finding that in the post-financial crisis era, informativeness of risk factor disclosures is significantly reduced. However, practitioner comments that litigation risk drives risk factor disclosure complexity suggest another important determinant of this difference.

The idea of litigation risk causing risk factor disclosure complexity derives from safe harbor provisions in the Private Securities Litigation Reform Act of 1995 ("PSLRA"). Under PSLRA, firms can seek safe harbor from private lawsuits based on forward-looking statements, if their forward-looking statements are accompanied by cautionary language. After the risk factor disclosure mandate, firms have used these disclosures to seek safe harbor protection by disclosing extensive cautionary language (Cazier et al., 2020), which ends up making the disclosure complex. I argue that in the presence of litigation risk, risk factor disclosures become more complex and less informative.

However, it is possible that litigation risk has no association with risk factor disclosure complexity and informativeness. Firms may be so risk averse that they always consider the highest possible litigation risk and provide for it in their disclosures. Or complexity may not matter to the market, and these disclosures may thus always convey information, regardless of

⁵ SEC concept release no. 33-10064 notes: "Despite the inclusion of generic risks, however, academic studies find that risk factor disclosure is informative and that the public availability of this information decreases information asymmetry among investors." This comment cites academic studies on risk factor disclosure informativeness.

their language. The impact of litigation risk on risk factor disclosure complexity, therefore, demands empirical examination.

In this paper, I use a measure called *Liberal court* (Huang et al., 2019), to understand the effect of litigation risk on risk factor disclosures. *Liberal court* measures the probability of having a liberal judge-dominated panel in a randomly selected 3-judge panel, given a circuit court of appeals. Huang et al., (2019) define liberal judges as those appointed by Democrat presidents and suggest that these judges are more anti-business, with the consequence that a more liberal court is linked to higher litigation risk for the firm. Since the appointment of liberal judges by the president is exogenous to firm choices and characteristics, using this measure allows me to see the impact of litigation risk on risk factor disclosure complexity cleanly.

I use complexity to infer poor informativeness of disclosures, since it is the opposite of using text content such as risk keywords, to infer high informativeness. While many risk keywords may exist in a disclosure (giving the researcher an impression of high informativeness), if they are presented in a complex manner, it is difficult for a reader to understand the information in the disclosure. I use three measures to proxy for language complexity – average sentence length, unique vocabulary count, (inspired from finance/accounting literature) and type-token ratio (borrowed from linguistics and communications literature.)

In my analysis, I find, for all three of my proxies, that when firms anticipate litigation risk, their risk factor disclosures become more complex. This is consistent with firms taking a protective approach and trying to make risk discussions more extensive to safeguard themselves from potential shareholder litigation – in line with industry/SEC observations. I then test and find that firms that perform poorly, as well as those with other bad news indicators, and those in the initial stages of their existence, all react more strongly to litigation risk by making their risk factor disclosures more complex. This is consistent with firms more prone to

(or averse to) shareholder lawsuits perceiving their litigation risk to be higher and choosing more complex risk factor disclosure language.

In further analyses, I test whether risk factor disclosure complexity has any negative effects on information asymmetry. Prior research finds evidence of readability and complexity being associated with information asymmetry (Bushee et al., 2018), future volatility, and analyst dispersion (Bonsall et al., 2017; Loughran & McDonald, 2014). Therefore, we can expect a complex disclosure to be followed by divergent opinions. Alternately, complex language may convey that the firm itself is complex, and therefore be informative to the market. It could also be possible that risk factor disclosures are not important to the market, or that the market can see through language complexity, and so risk factor disclosure complexity does not elicit any market reaction. Using a stock bid-ask spread measure similar to the one created by Garfinkel (2009), I find that risk factor disclosure complexity is associated with higher information asymmetry around 10-K filing dates.

I check whether this association is pervasive to other disclosures in 10-K by running regressions of spread on complexity of Management Discussion and Analysis (MD&A) section and find the results to not be significant. This rules out the possibility that my findings on complexity-information asymmetry association reflect a phenomenon generalizable to all disclosures.

Finally, I examine whether management is involved in the risk factor disclosure drafting process by testing whether the litigation risk-risk factor disclosure complexity association is any different during manager change years, and do not find significant results. This supports the anecdotal evidence that risk factor disclosures are driven by legal counsel and not by the management.

In summary, I find that in the presence of litigation risk, firms choose risk factor disclosure language in a way that makes disclosures more complex, and that this complex language is associated with higher information asymmetry around 10-K filing dates. Further, firms that are more prone to shareholder lawsuits react more strongly to litigation risk than do other firms, and management does not have much contribution to the risk factor disclosure drafting process. My main results are robust to using state fixed effects and industry-demeaned dependent variables.

Although the SEC has, in August 2020, amended its rules on risk factor disclosures to make them more understandable (such as asking firms to provide a summary in bullet points for disclosure exceeding 15 pages, disclosing only “material” and not “most significant” risk factors, and disclosing general risk factors in a separate subsection), it is still important to empirically establish how litigation risk impacts the risk factor disclosure drafting process. Further, while the SEC may encourage shortening of risk factor disclosures, even shorter disclosures could become complex, compromising their understandability. Finally, it is also important to empirically establish how complex disclosures impact information asymmetry and how complex disclosures are in turn associated with litigation risk.

My study contributes to two major strands of literature. First, it contributes to the literature on risk factor disclosures. Existing literature finds an association between risk factor disclosures and litigation risk but does not answer whether litigation risk causes firms to make their risk factor disclosures more complex. It also does not answer if risk factor disclosure complexity has an impact on informativeness. This paper examines the direct impact of litigation risk on risk factor disclosure complexity and its impact on informativeness – which is the theme of industry criticism directed towards risk factor disclosures. In doing so, I look at risk factor disclosures from the perspective of consumers of financial statements. Further, in light of

industry criticism on risk factor disclosures, I attempt to analyze and present litigation risk as a mediator of difficult-to-understand risk factor disclosures.

Second, my study contributes to the literature on litigation risk, specifically in relation to firm disclosures. Most studies analyzing the association between litigation risk and firm disclosures have used management forecasts and their attributes as outcome variables of interest (e.g. Bourveau et al., 2018; Cao & Narayamoorthy, 2011; Dong & Zhang, 2019; Houston et al., 2019, etc.), primarily focusing on the quantitative aspect of disclosures. Literature examining qualitative disclosures is scant (e.g., Levy et al., (2018) use CFO speech tone in conference calls). Since qualitative disclosures offer a wider canvas for a) managers to express themselves, and b) researchers to understand managerial decision making – they are important tools that can expand our knowledge about the financial reporting process. I also add to this stream of literature by looking at mandatory disclosures, in contrast to managerial forecasts or conference calls, which have been the focus of current literature in this area.

The remaining part of this paper is organized as follows. [Section 2](#) discusses existing literature and develops the hypotheses. [Section 3](#) details the research design and describes the main variables. [Section 4](#) describes the data. [Section 5](#) lays down the results. [Section 6](#) explains the robustness tests, and [Section 7](#) concludes.

2. Literature review and hypothesis development

2.1. Literature on risk factor disclosures

Risk factor disclosure informativeness

Risk factor disclosure informativeness can be seen from two perspectives. First, risk factor disclosures are seen to be informative if characteristics that proxy for firm risks are associated with risk factor disclosures. In this branch of literature, risk factor disclosures have been found to be associated with future losses, operating losses, a decline in sales and lawsuits (Gaulin,

2017), and negative quarterly changes in earnings (Filzen, 2015). Campbell et al. (2019) find a positive association between tax risk keywords and future positive tax-related cash flows.

Second, risk factor disclosures are seen to be informative if the market reacts to them. In this branch of literature, the risk factor disclosure mandate has been found to be associated with CDS spreads and volatility (Chiu et al., 2018), analyst forecast errors, and volatility (Huang et al., 2021); updates to these disclosures have been associated with abnormal returns (Filzen, 2015); and their systematic and idiosyncratic risk content has been associated with beta and volatility of returns (Campbell et al., 2014).

Risk factor disclosure non-informativeness

Limited literature exists to support industry criticism of non-informative risk factor disclosures. Bao & Datta (2014) find, through a topic modeling approach, that 22 out of 30 topics within risk factor disclosures are not informative enough, and 3 (5) topics lead to increased (reduced) risk perception by investors. Balakrishnan & Bartov (2011) do not find any relation between negative sentiment score of risk section of the IPO prospectus with analyst forecasts. Most importantly, Beatty et al. (2019) find that before 2008, risk factor disclosure content was associated with reactions in the equity, options, and bond markets, as well as prediction of Z-score ranks, but post 2008 this association has significantly weakened.

Prior studies on risk factor disclosure informativeness have two features. One, they have either a small or no part of their sample belonging to post-financial crisis years⁶; and two, most studies use risk keyword counts to proxy for the information contained in these disclosures. As seen in examples in [Appendix B](#), risk factor disclosures may contain many risk keywords, but they

⁶ e.g. Kravet & Muslu (2013) use data from 1994-2007, Campbell et al. (2014) use data from 2005-08, Chiu et al. (2018) use 2003-2007 as sample period], and when they do, there is no distinction between pre- and post-crisis periods in their models [e.g. Campbell et al. (2019), Huang et al., (2021) and Filzen (2015) use data till 2010, Hope et al. (2016) use data till 2011, and Au et al. (2020) use data till 2013

could be presented in a way that either confuses or does not convey much information to the reader. A word count of risk keywords may, in such cases, still portray the disclosure as highly informative. Measuring the noise due to complex language would provide better insight if we wanted to know whether end users are able to understand and use these disclosures. My analysis attempts to use such measures for analysis.

Litigation risk and risk factor disclosures

From the perspective of financial statement preparers, risk factor disclosures are seen as tools to shield the firm from litigation risk, especially in light of safe harbor under PSLRA. The evidence in Huang et al. (2021) suggests that in presence of risk factor disclosures, firms are more willing to disclose voluntary information in the form of higher and more positive forward-looking statements, management forecasts, and forecasts that are more optimistic, precise, and longer in horizon. This indicates that risk factor disclosures provide firms security in dealing with litigation risk. This idea is supported by Cazier et al. (2020), who find that shorter and more specific risk factor disclosures are more likely to be judged as inadequate in the court of law, implying that risk factor disclosure language is useful in protecting firms in court.

Nelson & Pritchard (2016) find that the length of risk factor disclosures is positively associated with litigation risk, and higher litigation risk firms alter their disclosures after the risk factor disclosure mandate, but before the mandate, tend to keep their disclosures the same. They find a positive and significant association between litigation risk and readability, which disappears after the mandate. They suggest this to be on account of low litigation risk firms improving the quality of their risk factor disclosures post the 2005 mandate.

To summarize, literature finds evidence supporting firms' usage of risk factor disclosures as litigation shield, and risk factor disclosure language actually providing some safe harbor. This can be summarized best in the words of an industry professional, "risk factors have taken on

the dynamic of sitting in the corner of the legal department, and the corner of the financial reporting” (Berkman, 2018). However, we still do not know i) whether firms choose risk factor disclosure language to actively seek out safe harbor from litigation, ii) whether such choice results reduces or increases complexity, iii) whether this complexity in risk factor disclosures has any association with their informativeness, and iv) whether actual operational risks have any part to play in firms’ response to litigation risk. I attempt to answer these questions through the analyses in this paper.

2.2. Literature on litigation risk

In this section, I restrict the discussion of litigation risk literature to those studies that pertain to firm disclosures only. Studies on financial reporting as an antecedent to litigation risk find that timely revelation of earnings news (or even issuance of warnings) and optimism in disclosures are all associated with firms’ likelihood of litigation (Donelson et al., 2012; Rogers et al., 2011) – supporting the idea that disclosures can aid in the management of litigation risk.

Studies analyzing the effects of litigation risk on corporate disclosures can be segregated based on whether disclosures are mandatory or voluntary, qualitative or quantitative in nature.

Most studies on voluntary quantitative disclosures have looked at the association between litigation risk and management forecast characteristics such as forecast frequency (Bourveau et al., 2018; Dong & Zhang, 2019; Houston et al., 2019), probability of making forecasts (Cao & Narayanamoorthy, 2011; Houston et al., 2019), forecast horizon (Cao & Narayanamoorthy, 2011; Dong & Zhang, 2019), forecast precision and specificity (Dong & Zhang, 2019); likelihood of issuing quantitative forecasts (Cao & Narayanamoorthy, 2011) good news forecasts (Johnson et al., 2001), horizon, specificity and precision of forecasts (Rogers & Van Buskirk, 2009). Bourveau et al. (2018) look at voluntary 8-K frequency. Among *qualitative*

disclosures, Rogers & Van Buskirk (2009) look at earnings-related conference calls, and Levy et al. (2018) analyze the conference call speech tone of CFOs who are not on board.

In the mandatory disclosure space, Bourveau et al. (2018) analyze mandatory reporting quality, and Hopkins (2018) analyze the likelihood of restatements. There is less evidence on the association of litigation risk with mandatory disclosures, and lesser on mandatory disclosures that are qualitative in nature. Looking at mandatory qualitative disclosures informs us of how firms exercise their discretion to choose language when they do not have a choice in *making* the disclosure.

2.3. Hypothesis development

As noted above, literature finds that litigation risk (with the exception of derivative lawsuits-specific litigation risk) encourages firms to disclose more, especially when such disclosures pertain to bad news. In the context of risk factor disclosures, this means that informing investors of potential bad news can reduce the expected costs of securities litigation, and help refute claims that the firm did not warn investors of potential bad news outcomes (Gaulin, 2017). Mary Jo White, ex-chairman of SEC suggests that one source of disclosure complexity is the “company’s decision to take a defensive posture and disclose more information rather than less to reduce the risk of litigation claims that there was insufficient disclosure.” (White, 2013) That this decision is fruitful in avoiding litigation is revealed in the analysis of federal judgments by Cazier et al. (2020) who find that in judgments that hold risk factor disclosures adequate, almost 10% of the reasons cited include that risk factor language is extensive/lengthy/numerous⁷, and almost half of all the reasons include either that the language fulfilled the statutory requirement

⁷ For example, in the case of Smith & Wesson Holding Corp., the District Court of Massachusetts considered cautionary statements sufficient for the purpose of safe harbor by holding that “The statements are extensive and cover the ground identified by Plaintiffs as relevant.” It also mentions that “A cautionary statement must warn of the alleged misrepresentations sufficiently that “the risk of real deception drops to nil.”” In the case of General Growth Properties, the District Court of N. D. of Illinois mentions that “Identification of the principal contingencies that could cause actual results to differ from projections is sufficient.”

to warn investors of risks that could cause actual results to vary, or that language included the risk that actually transpired. They comment that their evidence suggests that “despite common assertions that risk factor disclosures are excessively boilerplate and lengthy, judges generally find this language to be adequate for firms to obtain safe harbor protection.”

Given firms’ incentives to take a defensive position and disclose more rather than fewer risks, I expect that firms that anticipate increased litigation risk would choose to discuss all possible risks, regardless of the likelihood of their occurrence, ending up with more complex disclosures. However, if firms perceive that clearer language would more likely get them safe harbor under PSLRA, they would make a special effort to make their disclosures *less* complex, in face of increased litigation risk. I express my first hypothesis in null form, as follows:

H1: Litigation risk is not associated with risk factor disclosure complexity

This association of firms’ litigation risk with risk factor disclosure complexity should be impacted by firm characteristics that either make them more *likely* to face shareholder lawsuits or make them more *averse* to facing such shareholder lawsuits. I, therefore, test whether firms that either perform poorly, have other characteristics that make them prone to shareholder lawsuits, or whose reputational concerns make them averse to shareholder lawsuits, respond any differently to litigation risk. I expect that firms more prone to, or averse to, shareholder lawsuits would react more strongly to litigation risk. However, it might be the case that regardless of their characteristics, firms might always consider themselves prone to shareholder lawsuits, or always be averse to shareholder lawsuits, regardless of firms’ conditions. In such a case, I do not expect to see any difference in the association between litigation risk and risk factor disclosure complexity for different firms based on their characteristics.

Next, to understand whether complex language matters for informativeness, it is important to see the association of complex risk factor disclosure language with information asymmetry.

Disclosure complexity can, on the one hand, be an expression of firm complexity and thus inform investors of the same, thereby increasing informativeness. Alternately, complex language can reduce informativeness by making the text difficult to comprehend. Alternately still, if risk factor disclosures do not matter to the market, complexity can have no association with information asymmetry. The second hypothesis, in null form, is as follows:

H2: Risk factor disclosure complexity is not associated with information asymmetry

Finally, I examine whether firms' response to litigation risk involves inputs from the management. Extant industry reports have noted the extensive involvement of legal teams in risk factor disclosure drafting⁸. I test whether there is any difference in firm response to litigation risk depending on whether a new CEO has taken office. If management participates in the drafting of risk factor disclosures, as is ideally expected, CEO changes should bring about changes in firm responses to litigation risk due to varying levels of risk aversion of individuals taking on the CEO role. If management does not participate in the drafting of risk factor disclosures, I do not expect to see any differences in firm response to litigation risk around CEO changes.

3. Research Design and Variable Measurement

3.1. Text scores

I use Python to compute the following text scores of risk factor disclosures to proxy for language complexity:

⁸ E.g., there is anecdotal evidence that companies trying to streamline risk factor disclosures face resistance from legal counsel (EY, 2014). An industry participant remarked "Risk factors have taken on the dynamic of sitting in the corner of the legal department, and the corner of the financial reporting," and another industry professional admitted, "risk factor disclosure is largely driven by the fear of securities litigation" (Berkman, 2018)

Average sentence length: Also used by Loughran & McDonald (2014), it counts the average number of words in a sentence in a disclosure. Lengthier sentences (higher average sentence length) are considered more complicated to understand.

Unique Vocabulary: (Loughran & McDonald, 2014) create a measure called *vocabulary score*, which counts the number of unique words in the document that belong to Loughran and McDonald's master dictionary, divided by the total words contained in the master dictionary⁹. I take this measure but do not divide by total words in the master dictionary, for ease of interpretation. More words used from the dictionary suggests higher complexity of language being used.

Type-token ratio: A measure borrowed from the linguistics and communication literature, this is the ratio of the total number of distinct words in a disclosure (called "types") to the total number of words in the same disclosure (called "tokens"). Here, all word forms of the same word are not considered distinct (e.g., "is", "be", and "are", are the same type, "be"). This measure is used to denote lexical complexity and lexical proficiency in spoken and written communication. The higher the type-token ratio, the higher the proficiency of the communicator, and the higher the proficiency needed by the recipient of the communication, meaning more complexity. In a hypothetical, extreme case, there is no repetition of any word, including its different forms, meaning that every token is a different "type", thus making the numerator and denominator the same, making the ratio 1. A higher ratio, therefore, denotes more complexity.

3.2. Litigation risk measure

To proxy for litigation risk, I use the judge ideology measure created by Huang et al. (2019).

⁹ This dictionary is constructed using the English word list of 2of12inf dictionary and extended using words contained in 10-Ks not existing in the 2of12inf word list.

They measure litigation risk as the probability that a 3-judge panel selected from among the judges in the US Court of Appeals will be dominated by liberal judges. Judges appointed by Democrat presidents are taken to be liberal judges. Huang et al. (2019) compute this measure monthly, and I take the value of the measure for the last month of the fiscal year of the firm, for the circuit court that has jurisdiction over the headquarter state of the firm. This is consistent with the approach taken by Huang et al. (2019). In their sample, they find that 87% of securities class action lawsuits are filed according to the headquarter states of firms. In my sample, I find that almost 72% of securities class action lawsuits are filed in firms' headquarter states.

Since the appointment of liberal judges by the president is exogenous to firm choices and characteristics, using this measure helps reduce endogeneity in tests. One could argue that firms can choose to have their headquarters in a state with less liberal courts, but even then, it may not be easy to predict retirements, resignations, new appointments, and changes in political regimes making appointments.

3.3. Information asymmetry measure

I calculate the daily bid-ask spread for each firm's security using daily level data from CRSP by dividing the Ask – Bid price for the firm's stock on that day by the average of the Ask + Bid price for the firm's stock on the same day¹⁰. I then average this daily value over [0,3] days, [0,5] days or [0,7] days around the 10-K filing date. I use each of these three to conduct analyses on information asymmetry.

3.4. Modeling the influence of litigation risk on risk factor disclosures

For my first hypothesis, I model risk factor disclosure complexity as a function of litigation

¹⁰ This is similar to (Garfinkel, 2009) who uses TAQ data to arrive at an average daily bid-ask spread. He uses $[(ask-bid)/(ask+bid)/2]$ at intra day level and then averages all values of the day to arrive at an average value for the entire day, which he then uses for analysis. In his analysis he uses intra day data to arrive at daily values, whereas I use daily data to arrive at yearly values.

risk faced by the firm. The following describes my model:

$$\begin{aligned}
 &RFD_complexity_{i,t} \\
 &= \beta_0 + \beta_1 Liberal_court_{i,t} + \sum_{k=2}^{18} \beta_k Controls_{i,t} + IndustryFE + YearFE \\
 &+ \varepsilon
 \end{aligned}
 \tag{1}$$

Where,

$RFD_complexity_{i,t}$ is one of Average Sentence Length, Unique Vocabulary, or Type-Token Ratio.

$Liberal_court_{i,t}$ is the measure of litigation risk described in the preceding paragraphs.

$Controls_{i,t}$ includes firm-level controls which are associated with risk and disclosures, such as the time elapsed since the firm makes its first appearance on Compustat, $Firm_Age_{i,t}$; absolute accruals scaled by total assets, $Avg_Accruals_{i,t}$; indicator for Big N auditors, $BigN_{i,t}$; book to market ratio, $BTM_{i,t}$; income before extraordinary items, $Income_{i,t}$; leverage of the firm, $Leverage_{i,t}$; the natural log of the firm's market value, $Size_{i,t}$; a dummy for loss-making firms, $Loss_{i,t}$; daily abnormal stock returns for the 250 trading day period ending two trading days before the 10-K release, $Abn_return_{i,t}$; standard deviation of excess daily abnormal stock returns for the 250 trading day period ending two trading days before the 10-K release (calculated using the market model), $Stderet_{i,t}$; beta of the firm computed using the market model for the 250 trading day period ending two trading days before the 10-K release, $Beta_{i,t}$; skewness of daily returns for the 250 trading day period ending two trading days before the 10-K release, $Returns_skewness_{i,t}$; return on assets, $ROA_{i,t}$; average daily share turnover (expressed as a percentage) for the 250 trading day period ending two trading days before the

10-K release, $Sh_turn_{i,t}$; natural log of risk factor disclosure length, $Ln_RFDLength_{i,t}$; and Altman's Z score, $ZScore_{i,t}$. I also include $Lit_Risk\ KS_{i,t}$, the litigation risk measure created by (Kim & Skinner, 2012) to proxy for inherent characteristics of the firm that increase the likelihood of the firm facing litigation. I include industry and year fixed effects and cluster standard errors by firm. All variables are defined in [Appendix A](#).

If firms create disclosures protectively and choose to disclose even less relevant and/or less probable risks to seek safe harbor in the face of increased shareholder litigation, I expect β_1 in model (1) to be positive and significant. If firms consider that simpler language would afford them higher protection against litigation, β_1 should be negative.

To test whether firms' response to litigation risk is shaped by characteristics that either make them more prone to, or avoidant of, shareholder lawsuits, I run cross-sectional tests with proxies for poor performance, other bad news, and aversion to shareholder lawsuits. I use poor performance as a factor that makes firms more prone to shareholder lawsuits, based on literature that finds that lawsuits are routinely filed against firms whenever there is a significant drop in stock price (Huang et al., 2019). I use three proxies for poor performance – negative cash flow from operations, below median return on assets, and negative change in earnings from the previous year. To proxy for other bad news, I use the litigation risk measure created by Kim & Skinner, (2012) because it takes into account multiple inherent firm characteristics that expose firms to shareholder lawsuits. I also use short interest as a measure for bad news, because prior literature notes that short sellers can detect bad news hoarding by firms (Callen & Fang, 2015) – something that when revealed can invite potential shareholder lawsuits. Finally, I use early stages of the firm (CEO tenure) as a firm characteristic that is likely to make firms (CEOs) concerned about their reputation, and thus more averse to litigation, because prior literature has found reputation effects of securities litigation (e.g., Autore et al., 2014). For this, I use firm-years with below median firm age (CEO tenure) as proxy.

For all these tests, I create indicator variables representative of firm-years expected to be more prone to/avoidant of shareholder lawsuits and include them separately and as interaction with *Liberal court*, my measure of litigation risk in model (1). A positive and significant coefficient on the interaction variable supports the story that firms with higher concern for shareholder lawsuits (either through characteristics that make them more prone to shareholder lawsuits, or other conditions that make them more fearful of shareholder lawsuits) react more strongly to anticipated litigation risk.

For my second hypothesis, I model bid-ask spread as a function of risk factor disclosure complexity. The following describes my model:

$$\begin{aligned}
 Spread_{i,t} = & \beta_0 + \beta_1 RFD_complexity_{i,t} + \sum_{k=2}^{18} \beta_k Controls_{i,t} + IndustryFE + YearFE \\
 & + \varepsilon
 \end{aligned}
 \tag{2}$$

Where, $Spread_{i,t}$ is the bid-ask spread described in the preceding paragraphs. I run my models using three different windows of bid-ask spreads, and $Controls_{i,t}$ are the same as in Equation (1).

If risk factor disclosure complexity leads to poorer understanding among readers of financial statements, β_1 in equation (2) should be positive. However, if complex language is informative of firm complexity, I expect the bid-ask spread to go down in presence of complex language, making β_1 negative.

I then conduct placebo tests to see whether the complexity-information asymmetry association can be generalized to other disclosures. I expect to see a significant β_1 when risk factor

disclosure complexity is replaced with MD&A complexity in equation (2), with the sign on β_1 being similar to the previous test.

Finally, I examine management involvement in risk factor disclosure drafting by testing whether firms' response to litigation risk is any different during CEO-change years. I create an indicator variable that takes value 1 for firm-years where a new CEO took over, and interact it with *Liberal court*, my measure of litigation risk. If CEOs are involved in risk factor disclosure drafting, I expect to see a significant coefficient on the interaction term, with a positive coefficient denoting more cautious CEOs, and a negative coefficient denoting overconfident CEOs.

4. Data and Sample

My sample starts in 2009 to ensure that I only capture effects after the financial crisis since the informativeness of risk factor disclosures changed in the post-financial crisis period (Beatty et al., 2019). My sample ends in 2018. I obtain the text of risk factor disclosures from Calcbench. Sample construction has been summarized in [Table 1](#).

The litigation risk measure used is the *Liberal court* measure created by Huang et al. (2019) using judge ideology and has been obtained from the authors of the paper. The data on firm headquarters to match the judge ideology data comes from Bill McDonald's website¹¹. Data for computing bid-ask spreads is obtained from CRSP. Data on control variables and partitioning variables is from CRSP, Compustat, Execucomp, Thomson Reuters Institutional (13F) holdings stock ownership summary database, and Compustat Supplemental Short Interest file.

5. Results

¹¹ Augmented 10-X header data accessed from <https://sraf.nd.edu/data/augmented-10-x-header-data/>

[Table 2](#) presents the summary statistics, segregated into observations with below and above median *Liberal court* scores. Column (13) presents the significance of the univariate test of differences between means of below and above median observations. Univariate tests show that mean values for average sentence length and unique vocabulary are higher in the above median *Liberal court* subsample, but the mean type-token ratio is *lower* in the above median subsample. Compared to these, the mean differences of MD&A complexity measures are much smaller in magnitude than the differences seen in the risk factor disclosure complexity measures. Observations in the below-median *Liberal court* subsample are larger in size; have a higher book-to-market ratio, leverage, ROA, and beta; are older, and more likely to employ Big N auditors. Observations in below median *Liberal court* subsample also have lower inherent litigation risk measured by the Kim and Skinner proxy, but the magnitude is much smaller, almost a tenth of the standard deviation. Observations in the above median *Liberal court* subsample have both, higher average income, as well as a higher likelihood of incurring losses. Income in the above median subsample also has a higher standard deviation. The above median subsample also has a higher mean standard deviation of excess returns, skewness of daily returns, share turnover, and longer length of disclosures. All variables are defined in [Appendix A](#).

5.1. Litigation risk and risk factor disclosure complexity

My first hypothesis deals with the association of external litigation risk and risk factor disclosure complexity. [Table 3](#) presents the results. All odd numbered columns contain results without fixed effects, and all even numbered columns contain results with industry fixed effects and year fixed effects. The coefficients on *Liberal court* are positive and significant in all three regressions. These results are consistent with firms taking a defensive position and disclosing all possible risks, thereby making the disclosures complex. In terms of economic significance, a one standard deviation (“sd”) change in *Liberal court* leads to almost a 6% of sd, 1.75% of

sd, and 1.25% of sd change in average sentence length, unique vocabulary, and type-token ratio respectively. This suggests that higher expected litigation risk is associated with higher complexity in risk factor disclosure language.

5.2. Litigation risk-risk factor disclosure association for firms that are more prone to shareholder lawsuits

Next, I test whether firm reactions to litigation risk are impacted by their current characteristics which make them more or less prone to, or avoidant of, shareholder lawsuits. If poor performance, bad news, and reputational concerns intensify firms' perceptions of their litigation risk, I expect that such firms will react more strongly to the anticipation of litigation risk in making their risk factor disclosures more complex.

[Table 4](#) tests whether firm-years with poor firm performance are linked to stronger reactions to litigation risk in terms of more complex risk factor disclosures. Columns (1) to (3) use indicator variable taking value 1 for firm-years with negative cash flow from operations (and 0 otherwise), columns (4) to (6) use indicator variable taking value 1 for firm-years with below median return on assets (and 0 otherwise), and columns (7) to (9) use indicator variable taking value 1 for firm-years in which there was a decrease in earnings vis-à-vis previous year (and 0 otherwise). I add an interaction of *Liberal court* with my indicator for poor performance to model (1), along with separately adding the indicator for poor performance. I find positive and significant coefficients on the interaction terms for two out of my three measures of risk factor disclosure complexity in all three proxies of poor performance, indicating that firms that perform poorly respond more strongly to litigation risk, in line with the expectation that poor performance makes firms more prone to shareholder lawsuits.

[Table 5](#) tests whether firm-years with other bad news are linked to stronger reactions to litigation risk. Columns (1) to (3) use the litigation risk measure created by (Kim & Skinner,

2012), which represents firms' likelihood of facing shareholder lawsuits based on several firm characteristics, and columns (4) to (6) use short interest as a measure of bad news hoarding by firms. I create separate indicator variables that take value 1 for above median values of both these proxies, and 0 otherwise. I use interactions of these variables along with these indicators themselves in my regressions. For both proxies, I find that my interaction terms show positive and significant coefficients with two out of my three measures of risk factor disclosure complexity. This suggests that firms that have other bad news which makes them more likely to face shareholder lawsuits, respond more strongly when they anticipate litigation risk.

[Table 6](#) tests whether firms/CEOs that can have potential reputational losses from shareholder lawsuits (and are therefore more averse to shareholder lawsuits) react more strongly to anticipating litigation risk. Columns (1) to (3) use an indicator variable that takes value 1 for firms whose age is below the median ("Young Firm"), and 0 otherwise, where age is the time since listing taken from Compustat, in the absence of actual incorporation date. Columns (4) to (6) use an indicator variable that takes value 1 for firms whose CEO tenure is below the median ("Early Tenure CEO"), and 0 otherwise. As before, I use interactions of these indicator variables with *Liberal court*, along with the indicator variables themselves in my regressions. I find that for two out of three of my dependent variables proxying for risk factor disclosure complexity, the coefficient on the interaction term is positive and significant when cross-sectional tests are done using young firms. However, the coefficients are not significant when cross-sectional tests are done using early-tenure CEOs. This suggests either that shareholder lawsuits do not have an impact on CEO reputation, or that CEO reputation does not matter while drafting risk factor disclosures. This could also be because the CEO, or top management has less say in drafting risk factor disclosures.

Taken together, my cross-sectional results from Tables 4 to 6 are suggestive of firm characteristics intensifying firms' perceptions of their litigation risk, and thus making them react more strongly to the anticipation of litigation risk.

5.3. Risk factor disclosure complexity and informativeness

My second hypothesis deals with the association between risk factor disclosure complexity and information asymmetry. The purpose of this set of tests is to check whether litigation risk-induced complexity has any effect on the market. I use the average stock bid-ask spread calculated for [0,3], [0,5], and [0,7] days around the 10-K filing date. The results are tabulated in [Table 7](#). Coefficients on all three measures of risk factor disclosure complexity are positive, in all three windows in which spreads are calculated. This evidence is consistent with risk factor disclosure complexity increasing information asymmetry in the market. In terms of economic significance, a one sd change in average sentence length (unique vocabulary, type-token ratio) leads to an almost 2.8-3.5% of sd (14-16% of sd, 13-15.5% of sd) change in stock bid-ask spreads.

Next, I run placebo tests with MD&A complexity in place of risk factor disclosure complexity to check whether disclosure complexity-information asymmetry association is generalizable to all disclosures. [Table 8](#) shows that complexity measures for MD&A do not have any effect on average stock bid-ask spreads of firms around 10-K filing dates. This is suggestive of the fact that complex language in MD&A disclosures does not impair information asymmetry in the market. In other words, evidence is consistent with disclosure complexity – information asymmetry association not necessarily being pervasive to all disclosures.

5.4. Difference in litigation risk-risk factor disclosure association around management changes

My final set of tests examine whether firm responses to litigation risk involve inputs from the management. For this, I find years in which a new CEO took over the firm, and create an indicator taking value 1 in these firm-years, and 0 otherwise, and interact this indicator variable with *Liberal court*. [Table 9](#) presents the results of these tests. I find that for all three dependent variables, the coefficient on this interaction is not significant. This is consistent with the story of low management involvement in the risk factor disclosure drafting process.

6. Robustness tests

It could be argued that risk factor disclosure complexity and *Liberal court*, my measure of litigation risk, are both driven by unobservable state-level characteristics which may be confounding my results. To confirm that this is not the case, I run my main model with (A) state fixed effects instead of industry fixed effects, and (B) state fixed effects in addition to industry fixed effects and year fixed effects. The results tabulated in [Table 10](#) indicate that my main results do not change if the specifications include state fixed effects. I also run my tests by demeaning my dependent variables with industry averages and rerun my main tests. The results tabulated in [Table 11](#) indicate that my main results are robust to industry-demeaned dependent variables.

7. Conclusion

Risk factor disclosures were intended to be a discussion of risks that made investment in a firm speculative or risky. However, regulatory and industry criticism has focused on the fact that these disclosures do not help understand firm risks on account of being generic, unclear, and voluminous, with comments that firms' desire to shield themselves from shareholder litigation is a major contributor to this complexity. I test whether firms' anticipation of litigation risk does indeed impact complexity in risk factor disclosure language, and then, whether this complexity is associated with impairment in information asymmetry. My use of *Liberal court*,

a judge ideology-based measure of litigation risk, allows me to address endogeneity concerns in my analyses. I find that in the face of litigation risk, firms choose their risk factor disclosure language in a way that ends up making them more complex, and that this reaction is stronger for firms that perform poorly, or have other bad news which makes them more prone to shareholder lawsuits. This reaction is also stronger for firms that have reputational concerns that make them averse to facing shareholder lawsuits.

In further tests, I find a positive association between risk factor disclosure complexity and information asymmetry around 10-K filing date. This complexity-information asymmetry association does not exist for management discussion and analysis (MD&A) section of the annual report. Finally, I also fail to find evidence of management involvement in the risk factor disclosure drafting process.

My results are consistent with firms taking a defensive approach and disclosing all possible risks with a view to seeking safe harbor from litigation, and in the process, making the language more complex and increasing information asymmetry. Evidence also suggests that firms that are more prone to, or averse to, shareholder lawsuits, perceive their litigation risk to be higher and therefore respond to litigation risk by making their risk factor disclosures more complex, compared to other firms.

These results provide empirical evidence for industry criticism, add to the evidence on non-informative disclosures in the risk factor disclosure informativeness debate, and add to the scarce literature on the impact of litigation risk on mandatory qualitative disclosures. These results are important to understand firms' motivation in the drafting of risk factor disclosures. Recently, SEC has amended rules for risk factor disclosures to make them more concise and understandable. Future studies can analyze whether regulatory changes have been able to address the litigation risk-complexity issues and create more useful disclosures.

Appendix A: Variable Definitions

Variable	Definition	Source
<u>Risk factor disclosure characteristics</u>		
Avg_SentLength	Average words in a sentence of the risk factor disclosure	Calcbench (disclosures)
Unique_Vocab	Number of unique words in the risk factor disclosure belonging to the master dictionary created by Loughran & Mcdonald	Calcbench (disclosures), Loughran and Mcdonald dictionary (Loughran & Mcdonald, 2011)
Type Token Ratio	Ratio of total number of distinct words in a risk factor disclosure (called “types”) to total number of words in the same disclosure (called “tokens”). Here, all word forms of the same word are not considered as distinct (e.g., “is”, “be”, and “are”, are the same type, “be”).	Calcbench (disclosures)
<u>Litigation risk measure</u>		
Liberal_Court	Judge ideology measure of litigation risk constructed by (Huang et al., 2019) and explained in Section 3.2	Provided by authors of the article
<u>Controls</u>		
Firm_Age	Time elapsed since the firm makes first appearance on Compustat	Compustat
Avg_Accruals	Absolute value of (NI-OANCF)/AT	Compustat
BigN	Dummy which takes value 1 if firm’s auditor is a Big N firm, 0 otherwise	Compustat
BTM	Book to market ratio, calculated using $SEQ/(PRCC_F*CSHO)$	Compustat
Income	IB (i.e., income before extraordinary items)	Compustat
Leverage	Book value of total debt divided by total assets, $(DLTT+DD1)/AT$, DD1 is taken as 0 wherever missing	Compustat
Size	Natural log of firm’s market value, where market value is calculated as $PRCC_F*CSHO$	Compustat
Loss	Dummy that takes value 1 if IB (i.e., income before extraordinary items) is negative for the firm year, 0 otherwise	Compustat
Abn_Return	Daily abnormal stock returns for the 250 trading day period ending two trading days before the 10-K release, computed using the market model.	CRSP
Stderet	Standard deviation of daily abnormal stock returns for the 250 trading day period ending two trading days before the 10-K release, computed using the market model.	CRSP

Beta	Beta of the firm computed using market model for the 250 trading day period ending two trading days before the 10-K release.	CRSP
Returns Skewness	Skewness of daily returns for the 250 trading day period ending two trading days before the 10-K release	CRSP
ROA	Return on assets, NI/AT	Compustat
Sh_Turn	Average daily share turnover (expressed as a percentage) for the 250 trading day period ending two trading days before the 10-K release, in line with (Campbell et al., 2014)	CRSP
Ln_RFDLength	Natural log of the length of the risk factor disclosure	Calcbench (disclosures)
ZScore	Altman's Z-Score, computed as $1.2*WCAP/AT + 1.4*RE/AT + 3.3*EBIT/AT + 0.6*(PRCC_F*CSHO)/LT + SALE/AT$	Compustat
Lit_Risk KS	Litigation risk measure created by (Kim & Skinner, 2012)	Compustat, CRSP
<u>Bid-ask spread</u>	Average of daily (Ask-Bid)/(Ask+Bid/2) for [0, 3] days relative to 10-K filing date, or [0, 5] days relative to 10-K filing date, or [0, 7] days relative to 10-K filing date	CRSP
<u>MD&A disclosure characteristics</u>		
MD&A Avg_SentLength	Average words in a sentence of the Management Discussion and Analysis (MD&A) disclosure	Calcbench (disclosures)
MD&A Unique_Vocab	Number of unique words in the MD&A disclosure belonging to the master dictionary created by Loughran & Mcdonald	Calcbench (disclosures), Loughran and Mcdonald dictionary (Loughran & Mcdonald, 2011)
MD&A Type Token Ratio	Ratio of total number of distinct words in a MD&A disclosure (called "types") to total number of words in the same disclosure (called "tokens"). Here, all word forms of the same word are not considered as distinct (e.g., "is", "be", and "are", are the same type, "be").	Calcbench (disclosures)
Ln_MD&ALength	Natural log of the length of the MD&A disclosure	Calcbench (disclosures)
<u>Partitioning variables</u>		
Negative Cash Flow from Operations	Indicator variable equal to 1 if firm year has negative cash flow from operations and 0 otherwise, where cash flow from operations is the value of OANCF from Compustat	Compustat
Low ROA	Indicator variable equal to 1 if firm year has below median return on assets, where return on assets are calculated as per above definition	Compustat
Fall in Earnings	Indicator variable equal to 1 if the change in earnings, IB, compared to previous year is negative	Compustat
High Litigation Risk (Kim & Skinner)	Indicator variable equal to 1 if firm year has above median value for the litigation risk measure created by (Kim & Skinner, 2012)	Compustat, CRSP

High Short Interest	Indicator variable equal to 1 if firm year has above median value for short interest, where short interest is the average value of shares held short over the 12 months ending the month in which fiscal year ends, scaled by shares outstanding at the end of the fiscal year.	Compustat Supplemental Short Interest file
Young Firm	Indicator variable equal to 1 if value of Firm_Age is below the median value for the sample	Compustat
Early Tenure CEO	Indicator variable equal to 1 if CEO's tenure is below median value for the sample	Execucomp
CEO Change	Indicator variable equal to 1 for firm years in which a new CEO took over the role	Execucomp

Industry Demeaned Dependent Variables

Industry demeaned Avg_SentLength	Industry demeaned value of Avg_SentLength	Calcbench
Industry demeaned Unique_Vocab	Industry demeaned value of Unique_Vocab	Calcbench
Industry demeaned Type Token Ratio	Industry demeaned value of Type Toke Ratio	Calcbench

Appendix B: Examples of risk factor disclosures

Example 1: Excerpts from risk factor disclosure of Hospira Inc for the period ending December 2009 – Below median complexity scores

The Company is increasingly dependent on its outsourcing and third-party provider arrangements.

Hospira is becoming more dependent on its outsourcing arrangements, and if problems were to develop with respect to these arrangements, Hospira's business could be negatively impacted. Hospira is increasing its dependence on third-party providers for certain services, some of which include processes provided off-shore, including certain information technology, research and development, third party manufacturing, and finance and accounting outsourcing arrangements. The failure of these service providers to meet their obligations or the development of significant disagreements or other factors may materially disrupt Hospira's ongoing relationship with these providers or the services they provide could negatively affect operations.

Hospira is subject to the cost-containment efforts of wholesalers, distributors, third-party payors and government organizations.

Hospira relies on drug wholesalers to assist in the distribution of its generic injectable pharmaceutical products. In general, drug wholesalers have been attempting to implement a fee-for-service model for the distribution of such products. While Hospira has business arrangements in place with its major drug wholesalers, if Hospira is required to pay fees not contemplated by its existing arrangements, Hospira will incur additional costs to distribute its products, which may harm Hospira's profitability.

Hospira's products and services are sold to hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities which receive reimbursement for the healthcare services provided to their patients from third-party payors, such as government programs, private insurance plans and managed-care programs. These third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement for medical products and services. Levels of reimbursement, if any, may be decreased in the future, and future healthcare reform legislation, regulations or changes to reimbursement policies of third-party payors may otherwise adversely affect the demand for and price levels of Hospira's products, which could have a material adverse effect on Hospira's sales and profitability.

In markets outside the U.S., Hospira's business has experienced downward pressure on product pricing as a result of the concentrated buying power of governments as principal customers and the use of bid-and-tender sales methods whereby Hospira is required to submit a bid for the sale of its products. Hospira's failure to offer acceptable prices to these customers could have a material adverse effect on its sales and profitability in these markets.

If Hospira is unable to obtain or maintain its GPO and IDN pricing agreements, sales of its products could decline.

Many existing and potential customers for Hospira's products have combined to form GPOs, and IDNs in an effort to lower costs. A small number of GPOs influence a majority of sales to Hospira's hospital customers in the U.S. GPOs and IDNs negotiate pricing arrangements with medical supply manufacturers and distributors, and these negotiated prices are made available to a GPO's or an IDN's affiliated hospitals and other members. Failure to negotiate advantageous pricing and purchasing arrangements could cause Hospira to lose market share to its competitors and have a material adverse effect on its sales and profitability.

Hospira has pricing agreements covering certain products with the major GPOs in the U.S., including Amerinet, Inc.; Broadlane Inc.; HealthTrust Purchasing Group LP; MedAssets, Inc.; Novation, LLC; PACT, LLC; and Premier Purchasing Partners, LP. It is important for Hospira to continue to maintain pricing arrangements with major GPOs. In order to maintain these relationships, Hospira must offer a reliable supply of high-quality, regulatory-compliant products. Hospira also needs to maintain a broad product line and be price-competitive. Several GPO contracts are up for renewal or extension each year. Moreover, some of the agreements may be terminated on 60 or 90 days' notice, while others may not be terminated without breach until the end of their contracted term. If Hospira is unable to renew or extend one or more of those contracts, or one or more of the

contracts are terminated, and Hospira cannot replace lost business, Hospira's sales and profitability will decline. There has been consolidation among major GPOs, and further consolidation may occur. The effect of consolidation is uncertain, and consolidation may impair Hospira's ability to contract with GPOs in the future.

The GPOs also have a variety of business relationships with Hospira's competitors and may decide to enter into pricing agreements for, or otherwise prefer, products other than Hospira's. While GPOs negotiate incentives for members to purchase specified products from a given manufacturer or distributor, GPO pricing agreements allow customers to choose between the products covered by the arrangement and another manufacturer's products, whether or not purchased under a negotiated pricing agreement. As a result, Hospira may face competition for its products even within the context of its GPO pricing agreements.

Changes in the buying patterns of Hospira's customers could adversely affect Hospira's operating results.

During 2009, sales through the four largest wholesalers that supply products to many end-users accounted for approximately 42% of Hospira's global net sales. Hospira's profitability may be impacted by changes in the buying patterns of these wholesalers, or any other major distributor, or wholesale customer. Their buying patterns may change as a result of end-use buyer purchasing decisions, end-use customer demand, pricing, or other factors, which could adversely affect Hospira's results of operations.

Hospira and its suppliers and customers are subject to various governmental regulations, and it could be costly to comply with these regulations and to develop compliant products and processes. In addition, failure to comply with these regulations could subject us to sanctions which could adversely affect our business, results of operations and financial condition.

Hospira's products are subject to rigorous regulation by the FDA, and numerous other national, supranational, federal and state governmental authorities. The process of obtaining regulatory approvals to market a drug or medical device, particularly from the FDA and governmental authorities outside the U.S., can be costly and time-consuming, and approvals might not be granted for future products on a timely basis, if at all. To ensure ongoing customer safety, regulatory agencies such as the FDA may re-evaluate their current approval processes and may impose additional requirements. In addition, the FDA and others may impose increased or enhanced regulatory inspections for domestic or foreign plants.

The FDA, along with other regulatory agencies around the world, has been experiencing a backlog of generic drug and medical device applications, which has delayed approvals of new products. Those delays have become longer, and may continue to increase in the future. These delays can result in higher levels of unapproved inventory and increased costs due to excess and obsolescence exposures.

Existing regulations may also delay or prevent generic drug producers such as Hospira from offering certain products, such as biogeneric products in key territories, which could harm Hospira's ability to grow its business. If a clear regulatory pathway for the approval of biogeneric products is not fully developed in the U.S. and other jurisdictions, Hospira may not be able to generate future sales of such products in those jurisdictions and may not realize the anticipated benefits of its investments in the development, manufacture and sale of such products. Delays in receipt of, or failure to obtain, approvals for product candidates could result in delayed realization of product revenues and in substantial additional costs.

Hospira and Hospira's suppliers may not be able to remain in compliance with applicable FDA and other material regulatory requirements once it has obtained clearance or approval for a product. These requirements include, among other things, regulations regarding manufacturing practices, product labeling, advertising and postmarketing reporting, including adverse event reports and field alerts, some of which are related to manufacturing quality concerns. Hospira may be required by regulatory authorities, or determine on its own, to temporarily cease production and sale of certain products to resolve manufacturing and product quality concerns, which would harm Hospira's sales, margins and profitability in the affected periods and may have a material adverse effect on Hospira's business. For information related to the 2009 warning letter received by Hospira and other voluntary recalls and corrective actions in 2009, see the section captioned "Quality Assurance."

Hospira is also subject to various federal, state, and foreign laws pertaining to foreign corrupt practices and healthcare fraud and abuse, including anti-kickback and false claims laws. Violations of these laws are punishable by criminal and/or civil sanctions, including, in some instances, substantial fines, imprisonment and exclusion

from participation in national, federal and state healthcare programs, including Medicare, Medicaid, and Veterans' Administration health programs and health programs outside the U.S. These laws and regulations are broad in scope and are subject to evolving interpretations, which could require Hospira to alter one or more of its sales or marketing practices. In addition, violations of these laws, or allegations of such violations, could disrupt Hospira's business and result in a material adverse effect on Hospira's sales, profitability and financial condition.

For a more detailed listing of the laws and regulations that significantly affect Hospira's business and operations, see the section captioned "Governmental Regulation and Other Matters." Any adverse regulatory action, or action taken by Hospira to maintain appropriate regulatory compliance, with respect to these laws and regulations could disrupt Hospira's business and have a material adverse effect on its sales, profitability and financial condition. Furthermore, an adverse regulatory action with respect to any Hospira product, operating procedure or manufacturing facility could materially harm Hospira's reputation in the marketplace.

Hospira may continue to acquire other businesses and assets, license rights to technologies or products from third parties, form alliances, or dispose of businesses and assets, and any of these actions may not be completed in a timely or cost-effective manner, or at all.

As part of Hospira's business strategy, Hospira may continue to acquire other businesses and assets, license rights to technologies or products from third parties, form alliances, or dispose of businesses and assets, and any of these actions may not be completed in a timely or cost-effective manner, or at all. Hospira also may pursue strategic alliances to expand its product offerings and geographic presence. Hospira may not identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and may not realize the expected benefits of any acquisition, license arrangement, strategic alliance, or disposition. Other companies, including those with substantially greater resources, may compete with Hospira for opportunities. If Hospira is successful in securing certain opportunities, the products and technologies that Hospira acquires may not be successful or may require significantly greater resources and investments than originally anticipated. Hospira may not be able to integrate acquisitions successfully into its existing business.

To finance acquisitions, Hospira has incurred, and may continue to incur or assume significant debt. This significant indebtedness may require Hospira to dedicate a substantial portion of its cash flow from operations to servicing its debt, thereby reducing the availability of cash flow to fund capital expenditures, to pursue other acquisitions or investments in new technologies, and for general corporate purposes. In addition, this significant indebtedness may increase Hospira's vulnerability to general adverse economic conditions, including increases in interest rates. In addition, this may limit Hospira's flexibility in planning for, or reacting to, changes in or challenges relating to its business and industry. Hospira may incur greater than expected costs in connection with these transactions if it encounters difficulties or issues not known to it at the time of entering into the transaction. In addition, Hospira may enter markets in which it has no or limited prior experience. Hospira could experience negative effects on its reported results of operations from acquisition or disposition-related charges. Any of these negative effects could cause a downgrade of Hospira's credit rating, which would affect Hospira's ability to obtain new financing and negatively impact Hospira's cost of financing and credit.

Example 2: Excerpts from risk factor disclosure of Intersections Inc for the period ending December 2010 – Below median complexity scores

We are dependent upon our consumer products and services for substantially all of our revenue, and market demand for these services could decrease.

Approximately 99% of our revenue in 2009 and 2010 was derived from our consumer products and services, with the balance coming from our other services. We expect to remain dependent on revenue from our consumer products and services for the foreseeable future. Any significant downturn in the demand for these services would materially decrease our revenue.

If we lose our ability to purchase data from any of the three major credit reporting agencies, each of which is a competitor of ours, demand for our services could decrease.

We rely on the three major credit reporting agencies, Equifax, Experian and TransUnion, to provide us with essential data for our consumer identity theft protection and credit management services. Our agreements with Experian and TransUnion may be terminated by them on 30 days and 60 days notice, respectively. The term of our agreement with Equifax expires on December 31, 2011, but will renew for two additional one year terms unless we or Equifax provide notice of non-renewal 30 days prior to expiration. During any renewal term, either

party may terminate the agreement on 90 days prior notice, and the pricing we pay is subject to increase. Each of the three major credit reporting agencies owns its consumer credit data and is a competitor of ours in providing credit information directly to consumers, and may decide to stop supplying data to us. Any interruption, deterioration or termination of our relationship with one or more of the three credit reporting agencies would be disruptive to our business and could cause us to lose subscribers.

Our consumer products and services depend on data and technology from third party suppliers, and any failure of that data or those technologies or their suppliers could harm our products and services and our business.

In addition to the three major credit reporting agencies, we include other data and technology from third party suppliers in our consumer products and services, including public records data, identity theft risk assessments and alerts, anti-virus, anti-key logging and other computer software, mobile data storage technology, and an online privacy protection device. Any defect or failure in this data or technology, or failure of a third party data or technology supplier, could require us to remove the affected data or technology from our products and services, cause us to lose customers or clients, or expose us to liability claims by customers or clients arising out of the failure.

A failure of any of the insurance companies that underwrite the insurance products or related benefits provided as part of our consumer products and services, or refusal by those insurance companies to provide the expected insurance, could harm our business.

Certain of our consumer products and services include or depend on insurance products, or are dependent on group insurance policies under which the customers for our products and services are the insureds. The current and expected economic climate may cause financial instability among one or more of those insurance companies. Any failure of any of those insurance companies, or refusal by them to provide the expected insurance, could require us to remove the affected insurance from our products and services, cause us to lose customers or clients, or expose us to liability claims by our customers or clients.

We may incur substantial marketing expenses as we enter new businesses, develop new products or increase our direct marketing arrangements, which could cause our operating income to decline on a quarterly basis and our stock price to drop.

We are committing significant resources to our strategic effort to market our services to the broader direct-to-consumer marketplace. In addition, as we increase our direct marketing arrangements with new or existing clients, we bear most of the new subscriber marketing costs and pay our client a commission for revenue derived from subscribers. This generally results in higher marketing costs and negative cash flow over the first several months after a program is launched. This could cause our stock price to decline. In addition, we cannot assure you that our investment in the direct-to-consumer business or other new businesses or products or any increase in direct marketing arrangements will be successful in increasing our subscribers or generating future revenue or profits on our projected timeframes or at all, which could have a material adverse effect on our results of operations and financial condition.

If we experience system failures or interruptions in our telecommunications or information technology infrastructure, our revenue could decrease and our reputation could be harmed.

Our operations depend upon our ability to protect our telecommunications and information technology systems against damage or system interruptions from natural disasters, technical failures and other events beyond our control. We receive credit data electronically, and this delivery method is susceptible to damage, delay or inaccuracy. A significant portion of our business involves telephonic customer service as well as mailings, both of which depend upon the data generated from our computer systems. Unanticipated problems with our telecommunications and information technology systems may result in a significant system outage or data loss, which could interrupt our operations. Our infrastructure may also be vulnerable to computer viruses, hackers or other disruptions entering our systems from the credit reporting agencies, our clients and subscribers or other authorized or unauthorized sources.

We and our clients outsource telemarketing to third parties who may take actions that lead to negative publicity and consumer dissatisfaction.

We and our clients solicit some of our subscribers through outbound telemarketing that we outsource to third-party contractors. In outbound telemarketing, the third-party contractors make the initial contact with potential subscribers. We attempt to control the level and quality of the services provided by these third parties through a combination of contractual provisions, monitoring, on-site visits and records audits. In arrangements where we bear the marketing cost, which represented 60% of new subscribers acquired in 2010, approximately

48% of new subscribers were obtained through outbound telemarketing by outsourced vendors. In arrangements where the clients bear the marketing cost, which represented 40% of new subscribers acquired in 2010, approximately 15% of new subscribers were obtained through outbound telemarketing by outsourced vendors. Any quality problems could result in negative publicity and customer dissatisfaction, which could cause us to lose clients and subscribers and decrease our revenue.

We may lose subscribers and customers and significant revenue if our existing products and services become obsolete, or if we fail to introduce new products and services with broad appeal or fail to do so in a timely or cost-effective manner.

Our growth depends upon developing and successfully introducing new products and services that generate client and consumer interest, including new data sources, advanced tools and analytical capabilities, more timely notification of activities and more useable content. We have made or may make significant investments in these new products and services, including development costs and prepayment of royalties and fees to third party providers. Although we have a limited history of developing and introducing products and services outside the areas of identity theft protection and consumer credit management, we are currently developing or introducing new products and services in the area of small business credit information and fraud detection. If we fail to develop, introduce or expand successfully our products and services, our business and prospects will be materially adversely affected.

We may lose subscribers and significant revenue if our subscribers cease to maintain the accounts through which they are billed for our products and services, or our clients change their billing or credit practices or policies.

Most of our subscribers are billed for our products and services through accounts with our clients, such as mortgage and credit card accounts. Market factors such as a high degree of mortgage refinancing may result in cancellation of those accounts, which will result in a loss of subscribers. Client decisions, such as changes in their credit card billing practices or policies, may result in our inability to bill for our products and services, which also may result in a loss of subscribers. These subscriber losses may have a material adverse impact on our revenue.

We may not be able to develop and maintain relationships with third party providers, and failures by those third parties could harm our business and prospects.

Our consumer products and services are substantially dependent on third party data, analytics and technology providers, as well as third party call center and customer service providers. Our failure to develop and maintain these third party relationships could harm our ability to provide those services. Our other consumer products and services are substantially dependent on third party providers, including insurance companies and software distributors. Our other services are dependent on other third party providers, including third party data sources, technology providers and outsourced service centers. Failure of any of the third party providers on which we depend to perform under our agreements with them, or to provide effective and competent services, could cause us to have liability to others or otherwise harm our business and prospects.

Our senior secured credit agreement provides our lenders with a first-priority lien against substantially all of our assets and contains financial covenants and other restrictions on our actions, and it could therefore limit our operational flexibility or otherwise adversely affect our financial condition.

We may fail to comply with the covenants in our credit agreement as a result of, among other things, changes in our results of operations or general economic changes. These covenants may restrict our ability to engage in transactions that would otherwise be in our best interests. Failure to comply with any of the covenants under our credit agreement could result in a default under the facility, which could cause the lenders to accelerate the timing of payments and exercise their lien on substantially all of our assets, which would have a material adverse effect on our business, operations, financial condition and liquidity. In addition, because our credit agreement bears interest at variable interest rates, increases in interest rates would increase our cost of borrowing, resulting in a decline in our net income and cash flow, which could cause the price of our common stock to decline.

We may be unable to meet our future capital requirements to grow our business, which could adversely impact our financial condition and growth strategy.

We may need to raise additional funds in the future in order to operate and expand our business. There can be no assurance that additional funds will be available on terms favorable to us, or at all. Our inability to obtain additional financing could have a material adverse effect on our financial condition.

We depend on key members of our management and marketing personnel.

If one or more of these individuals, particularly our chairman and chief executive officer, were unable or unwilling to continue in their present positions, our business could be materially adversely affected. In addition, we do not maintain key person life insurance on our senior management. We also believe that our future success will depend, in part, on our ability to attract, retain and motivate skilled managerial, marketing and other personnel.

If we determine in the future that we are required to establish reserves or we incur liabilities for any litigation or governmental proceedings that has been or may be brought against us, our results of operations, cash flow and financial condition could be materially and adversely affected.

We have not established reserves for any of the legal or governmental proceedings in which we are currently involved and we are unable to estimate at this time the amount of charges, if any, that may be required to provide reserves for these matters in the future. We may determine in the future that a reserve or a charge for all or a portion of any of our legal proceedings is required, including charges related to legal fees. In addition, we may be required to record an additional charge if we incur liabilities in excess of reserves that we have previously recorded. Such charges, particularly in the event we may be found liable in a large class-action lawsuit, could be significant and could materially and adversely affect our results of operations, cash flow and financial condition and result in a significant reduction in the value of our shares of common stock.

Example 3: Excerpts from risk factor disclosure of Starbucks Corp for the period ending September 2018 – Above median complexity scores

You should carefully consider the risks described below. If any of the risks and uncertainties described in the cautionary factors described below actually occurs, our business, financial condition and results of operations, and the trading price of our common stock could be materially and adversely affected. Moreover, we operate in an increasingly competitive and rapidly changing environment. New factors emerge from time to time and it is not possible to predict the impact of all these factors on our business, financial condition or results of operations.

- ***Economic conditions in the U.S. and international markets could adversely affect our business and financial results.***

As a retailer that is dependent upon consumer discretionary spending, our results of operations are sensitive to changes in or uncertainty about macro-economic conditions. Our customers may have less money for discretionary purchases and may stop or reduce their purchases of our products or trade down to Starbucks or competitors' lower priced products as a result of job losses, foreclosures, bankruptcies, increased fuel and energy costs, higher interest rates, inflation, higher taxes, reduced access to credit, economic uncertainty and potential negative impacts relating to federal economic policy changes and recent international trade disputes. These factors may also result in a general downturn in the restaurant industry. Decreases in customer traffic and/or average value per transaction will negatively impact our financial performance as reduced revenues without a corresponding decrease in expenses result in sales de-leveraging, which creates downward pressure on margins and also negatively impacts comparable store sales, net revenues, operating income and earnings per share. There is also a risk that if negative economic conditions or uncertainty persist for a long period of time or worsen, consumers may make long-lasting changes to their discretionary purchasing behavior, including less frequent discretionary purchases on a more permanent basis.

- ***Our success depends substantially on the value of our brands and failure to preserve their value, either through our actions or those of our business partners, could have a negative impact on our financial results.***

We believe we have built an excellent reputation globally for the quality of our products, for delivery of a consistently positive consumer experience and for our global social impact programs. The Starbucks brand is recognized throughout the world and we have received high ratings in global brand value studies. To be successful in the future, particularly outside of the U.S., where the Starbucks brand and our other brands are less well-known, we believe we must preserve, grow and leverage the value of our brands across all sales channels. Brand value is based in part on consumer perceptions on a variety of subjective qualities.

Additionally, our business strategy, including our plans for new stores, branded products and other initiatives, relies significantly on a variety of business partners, including licensee and joint venture relationships, particularly in our international markets, and third-party manufacturers, distributors and retailers, particularly for our entire global Channel Development business. Licensees, retailers and foodservice operators are often authorized to use our logos and provide branded food, beverage and other products directly to customers. We provide training and

support to, and monitor the operations of, certain of these business partners, but the product quality and service they deliver may be diminished by any number of factors beyond our control, including financial pressures they may face. We believe customers expect the same quality of products and service from our licensed-store operators as they do from us and we strive to ensure customers receive the same quality of products and service experience whether they visit a company-operated store or a licensed store. We also source our food, beverage and other products from a wide variety of domestic and international business partners in our supply chain operations, and in certain cases such products are produced or sourced by our licensees directly. And although foodservice operators are authorized to use our logos and provide branded products as part of their foodservice business, we do not monitor the quality of non-Starbucks products served in those locations. Additionally, inconsistent uses of our brand and other of our intellectual property assets, as well as failure to protect our intellectual property, including from unauthorized uses of our brand or other of our intellectual property assets, can erode consumer trust and our brand value and have a material negative impact on our financial results.

Business incidents, whether isolated or recurring and whether originating from us or our business partners, that erode consumer trust, such as actual or perceived breaches of privacy or violations of domestic or international privacy laws, contaminated food, product recalls, store employees or other food handlers infected with communicable diseases or other potential incidents discussed in this risk factors section, particularly if the incidents receive considerable publicity, including rapidly through social or digital media (including for malicious reasons), or result in litigation, and failure to respond appropriately to these incidents (or being perceived to not have reacted appropriately), can significantly reduce brand value, trigger boycotts of our stores or products or demonstrations at our stores, result in civil and criminal liability and have a negative impact on our financial results. Consumer demand for our products and our brand equity could diminish significantly if we, our employees or our licensees or other business partners fail to preserve the quality of our products, act or are perceived to act in an unethical, illegal, racially-biased or unequal treatment basis or socially irresponsible manner, including with respect to the sourcing, content or sale of our products, service and treatment at Starbucks stores or the use of customer data for general or direct marketing or other purposes, fail to comply with laws and regulations, publicly take controversial positions or actions or fail to deliver a consistently positive consumer experience in each of our markets, including by failing to invest in the right balance of wages and benefits to attract and retain employees that represent the brand well.

- ***Incidents involving food or beverage-borne illnesses, tampering, adulteration, contamination or mislabeling, whether or not accurate, as well as adverse public or medical opinions about the health effects of consuming our products, could harm our business.***

Instances or reports, whether true or not, of unclean water supply or food-safety issues, such as food or beverage-borne illnesses, tampering, adulteration, contamination or mislabeling, either during growing, manufacturing, packaging, storing or preparation, have in the past severely injured the reputations of companies in the food and beverage processing, grocery and quick-service restaurant sectors and could affect us as well. Any report linking us to the use of unclean water, food or beverage-borne illnesses, tampering, adulteration, contamination, mislabeling or other food or beverage-safety issues could damage our brand value and severely hurt sales of our food and beverage products and possibly lead to product liability claims, litigation (including class actions) or damages. Clean water is critical to the preparation of coffee, tea and other beverages, as well as ice for our cold beverages, and our ability to ensure a clean water and ice supply to our stores can be limited, particularly in some international locations. We are also continuing to incorporate more products in our food and beverage lineup that require freezing or refrigeration, including produce (such as fruits and vegetables in our salads and juices), dairy products (such as milk and cheeses), non-dairy alternative products (such as soymilk and almondmilk), ice for our cold drinks and meats. We also face risk by relying on third-party food suppliers to provide and transport ingredients and finished products to our stores. We monitor the operations of certain of these business partners, but the product quality and service they deliver may be diminished by any number of factors beyond our control, which make it more difficult to detect contamination or other defect in these products. Additionally, we are evolving our product lineup to include more local or smaller suppliers for some of our products who may not have as rigorous quality and safety systems and protocols as larger or more national suppliers. If customers become ill from food or beverage-borne illnesses, tampering, adulteration, contamination, mislabeling or other food or beverage-safety issues, we could be forced to temporarily close some stores and/or supply chain facilities, as well as recall products. In addition, instances of food or beverage-safety issues, even those involving solely the restaurants or stores of competitors or of suppliers or distributors (regardless of whether we use or have used those suppliers or distributors), could, by resulting in negative publicity about us or the foodservice industry in general, adversely affect our sales on a regional or global basis. A decrease in customer traffic as a result of food-safety concerns or negative publicity, or as a result of a temporary closure of any of our stores, product recalls or food or beverage-safety claims or litigation, could materially harm our business and results of operations.

Some of our products contain caffeine, dairy products, sugar and other compounds and allergens, the health effects of which are the subject of public and regulatory scrutiny, including the suggestion that excessive consumption of caffeine, dairy products, sugar and other compounds can lead to a variety of adverse health effects. Particularly in the U.S., there is increasing consumer awareness of health risks, including obesity, due in part to increased publicity and attention from health organizations, as well as increased consumer litigation based on alleged adverse health impacts of consumption of various food and beverage products. While we have a variety of beverage and food items, including items that are coffee-free and have reduced calories, an unfavorable report on the health effects of caffeine or other compounds present in our products, whether accurate or not, imposition of additional taxes on certain types of beverages, or negative publicity or litigation arising from certain health risks could significantly reduce the demand for our beverages and food products and could materially harm our business and results of operations.

- ***The unauthorized access, use, theft or destruction of customer or employee personal, financial or other data or of Starbucks proprietary or confidential information that is stored in our information systems or by third parties on our behalf could impact our reputation and brand and expose us to potential liability and loss of revenues.***

Many of our information technology systems, such as those we use for our point-of-sale, web and mobile platforms, including online and mobile payment systems, delivery services and rewards programs, and for administrative functions, including human resources, payroll, accounting and internal and external communications, as well as the information technology systems of our licensees, franchisees and other third-party business partners and service providers, whether cloud-based or hosted in proprietary servers, contain personal, financial or other information that is entrusted to us by our customers and employees. Many of our information technology systems also contain Starbucks proprietary and other confidential information related to our business, such as business plans, product development initiatives and designs. Similar to many other retail companies and because of the prominence of our brand, we are consistently subject to attempts to compromise our information technology systems. To the extent we or a third party were to experience a material breach of our or such third party's information technology systems that result in the unauthorized access, theft, use, destruction or other compromises of customers' or employees' data or confidential information of the Company stored in such systems, including through cyber-attacks or other external or internal methods, it could result in a material loss of revenues from the potential adverse impact to our reputation and brand, our ability to retain or attract new customers and the potential disruption to our business and plans. Such security breaches also could result in a violation of applicable U.S. and international privacy and other laws, and subject us to private consumer, business partner, or securities litigation and governmental investigations and proceedings, any of which could result in our exposure to material civil or criminal liability. For example, the European Union adopted a new regulation that became effective in May 2018, called the General Data Protection Regulation ("GDPR"), which requires companies to meet new requirements regarding the handling of personal data, including its use, protection and transfer and the ability of persons whose data is stored to correct or delete such data about themselves. Failure to meet the GDPR requirements could result in penalties of up to 4% of annual worldwide revenue. The GDPR also confers a private right of action on certain individuals and associations. Our reputation and brand and our ability to attract new customers could also be adversely impacted if we fail, or are perceived to have failed, to properly respond to these incidents. Such failure to properly respond could also result in similar exposure to liability.

Compliance with the GDPR and other applicable international and U.S. privacy, cybersecurity and related laws can be costly and time-consuming. Significant capital investments and other expenditures could also be required to remedy cybersecurity problems and prevent future breaches, including costs associated with additional security technologies, personnel, experts and credit monitoring services for those whose data has been breached. These costs, which could be material, could adversely impact our results of operations in the period in which they are incurred and may not meaningfully limit the success of future attempts to breach our information technology systems.

Media or other reports of existing or perceived security vulnerabilities in our systems or those of our third-party business partners or service providers can also adversely impact our brand and reputation and materially impact our business, even if no breach has been attempted or has occurred. Additionally, the techniques and sophistication used to conduct cyber-attacks and breaches of information technology systems, as well as the sources and targets of these attacks, change frequently and are often not recognized until such attacks are launched or have been in place for a period of time. We continue to make significant investments in technology, third-party services and personnel to develop and implement systems and processes that are designed to anticipate cyber-attacks and to prevent or minimize breaches of our information technology systems or data loss, but these security measures cannot provide assurance that we will be successful in preventing such breaches or data loss.

- *We rely heavily on information technology in our operations and growth initiatives, and any material failure, inadequacy, interruption or security failure of that technology could harm our ability to effectively operate and grow our business and could adversely affect our financial results.*

We rely heavily on information technology systems across our operations, including for administrative functions, point-of-sale processing and payment in our stores and online, management of our supply chain, Starbucks Cards, online business, delivery services, mobile technology, including mobile payments and ordering apps, reloads and loyalty functionality and various other processes and transactions, and many of these systems are interdependent on one another for their functionality. Additionally, the success of several of our initiatives to drive growth, including our priority to increase digital relationships with our customers to drive incremental traffic and spend, is highly dependent on our technology systems. Our ability to effectively manage our business, launch digital and other initiatives, and coordinate the production, distribution, administration and sale of our products depends significantly on the reliability, integrity and capacity of these systems. We also rely on third-party providers and platforms for some of these information technology systems and support. Additionally, our systems hardware, software and services provided by third-party service providers are not fully redundant within a market or across our markets. Although we have operational safeguards in place, they may not be effective in preventing the failure of these systems or platforms to operate effectively and be available. Such failures may be caused by various factors, including power outages, catastrophic events, physical theft, computer and network failures, inadequate or ineffective redundancy, problems with transitioning to upgraded or replacement systems or platforms, flaws in third-party software or services, errors or improper use by our employees or third party service providers, or a breach in the security of these systems or platforms, including through cyber-attacks such as those that result in the blockage of our or our third-party business partners' or service providers' systems and platforms and those discussed in more detail in this risk factors section. If our incident response, disaster recovery and business continuity plans do not resolve these issues in an effective manner they could result in an interruption in our operations and could cause material negative impacts to our product availability and sales, the efficiency of our operations and our financial results. In addition, remediation of any problems with our systems could result in significant, unplanned expenses.

Example 4: Excerpts from risk factor disclosure of Omega Protein Corp Inc. for the period ending December 2010 – Above median complexity scores

Fluctuation in the “total yield” derived from Omega Protein’s fish catch could impact the Company’s ability to operate profitably. The “total yield,” or the percentage of fish meal, fish oil and fish solubles products derived from the menhaden fish has fluctuated over the years and from month to month due to natural conditions relating to fish biology over which Omega Protein has no control. For example, Omega Protein’s total yield for the 2010 fishing season was 7% lower compared to the average total yield the previous five fishing seasons. The Company believes that the causes of lower total yields relate to fish diet, weather and water temperature but such causes are not generally well understood. In addition, as a result of the Gulf of Mexico oil spill disaster, a greater percentage than normal of Omega Protein’s 2010 fish catch was harvested at its Reedville, Virginia facility which typically has lower total yields as compared to the yields from Omega Protein’s Gulf of Mexico facilities. Gulf of Mexico total yields were consistent with the previous five fishing seasons while Atlantic yields were approximately 13% lower as compared to the average total yield of the previous five fishing seasons. Poor total yields result in increased per unit inventory costs and fewer volumes available for future sale and, as a result, have at times materially impacted the amount of products that Omega Protein has been able to produce from its available fish catch. It is possible that total yields in the future could adversely impact the Company’s ability to operate profitably.

Laws or regulations that restrict or prohibit menhaden or purse seine fishing operations, or the manufacture, sale or distribution of menhaden products, could adversely affect Omega Protein’s ability to operate. The adoption of new laws or regulations at federal, regional, state or local levels that restrict or prohibit menhaden or purse seine fishing operations, or the manufacture, sale or distribution of menhaden products, or stricter interpretations of existing laws or regulations, could materially adversely affect Omega Protein’s business, results of operations and financial condition. In addition, the impact of a violation by Omega Protein of federal, regional, state or local law or regulation relating to its fishing operations, the protection of the environment or the health and safety of its employees could have a material adverse affect on the Company’s business, financial condition, or results of operation.

One example of potentially restrictive regulation is an addendum to a fisheries management plan recommended by a regional regulatory commission, the Atlantic States Marine Fisheries Commission (“ASMFC”), in August 2005. The Commonwealth of Virginia has declined to adopt the ASMFC’s recommended plan but has instead adopted its own restrictions whereby Omega Protein’s Chesapeake Bay menhaden harvest

are capped for a five year period at 109,020 metric tons per year. The Virginia restrictions also allow for a credit whereby any under-harvest in a particular year below the 109,020 metric ton cap would be added to increase the cap for the following year, up to a maximum of 122,740 metric tons per year. Omega Protein supported Virginia's proposal and voluntarily complied with its limitations in 2006 and subsequently thereafter after the cap was formally approved. This restriction had no effect on the Company's Chesapeake Bay harvest in 2007, 2008, 2009 and 2010 and is not expected to have a material adverse effect on the Chesapeake Bay harvest in 2011. As a result of Omega Protein's 2010 Chesapeake Bay underharvest, the 2011 Chesapeake Bay catch limit will be 122,740 metric tons. The ASMFC and Virginia have recently extended the cap for another three year period so that it now expires in 2013. See "Items 1 and 2 Business and Properties—Regulation".

Another example is regulations adopted by the Texas Parks and Wildlife Commission related to the menhaden reduction fishery in Texas waters which limits the Total Allowable Catch ("TAC") to 31.5 million pounds annually. The regulations also allow for a 10% underage or overage in each year which is credited or deducted, as applicable, to the TAC in the following year.

Another example is two bills that would have banned commercial menhaden fishing introduced in October 2007 in the U.S. House of Representatives (H.R. 3840 and H.R. 3841) by two congressmen representing portions of New Jersey and Maryland, areas where Omega Protein has no operations. The bills were never moved out of committee. Another bill introduced in the U.S. Senate in October 2009 (S. 1816) would have placed a moratorium on menhaden fishing on the Atlantic Coast. This moratorium provision was later removed from the proposed bill. In the 2011 session of the Virginia legislature, a House bill was introduced that would have mandated a reduction in menhaden reduction fishing in Virginia waters by 20% each year, ending in a complete moratorium after five years. The bill was never moved out of committee.

Another example is a bill introduced in February 2011 in the Maryland House of Delegates (House Bill 1142) which would prohibit the manufacture, sale or distribution in the State of Maryland of products obtained from reduction of Atlantic menhaden. The Company is unable to predict the outcome of this bill.

The enactment of these bills described above, or any restrictions similar to those described in these bills, could have a material adverse effect on the Company's business, results of operations or financial condition.

Worldwide supply and demand relationships, which are beyond the Company's control, influence the prices that the Company receives for many of its products and may from time to time result in low prices for many of the Company's products. Prices for many of the Company's products are subject to, or influenced by, worldwide supply and demand relationships over which the Company has no control and which tend to fluctuate to a significant extent over the course of a year and from year to year. For example, during 2008, Omega Protein experienced fish oil price increases of approximately 73.4% when compared to 2007. Beginning in the third quarter of 2008, pricing in the agricultural commodity markets began to decrease. Spot fish oil and fish meal prices have followed these general trends by decreasing during the second half of 2008 and throughout 2009. During 2009, Omega Protein's fish oil prices declined approximately 35.1% as compared to 2008. During 2010, Omega Protein's fish meal prices increased approximately 40.2% as compared to 2009 due in part to the global tightening of fish meal availability. The factors that influence these supply and demand relationships are world supplies of fish meal made from other fish species, animal proteins and fats, palm oil, rapeseed oil, soy meal and oil, and other edible oils.

New laws or regulation regarding contaminants in fish oil or fish meal may increase Omega Protein's cost of production or cause Omega Protein to lose business. It is possible that future enactment of increasingly stringent regulations regarding contaminants in fish meal or fish oil by foreign countries or the United States may adversely affect the Company's business, results of operations and financial condition. More stringent regulations could result in: (i) Omega Protein's incurrence of additional capital expenditures on contaminant reduction technology in order to meet the requirements of those jurisdictions, and possibly higher production costs for Omega Protein's products, or (ii) Omega Protein's withdrawal from marketing its products in those jurisdictions.

Omega Protein's fish catch may be impacted by restrictions on its spotter aircraft. If Omega Protein's spotter aircraft are prohibited or restricted from operating in their normal manner during the Omega Protein's fishing season, the Company's business, results of operations and financial condition could be adversely affected. For example, as a direct result of the September 11, 2001 terrorist attacks, the Secretary of Transportation issued a federal ground stop order that grounded certain aircraft (including Omega Protein's fish-spotting aircraft) for approximately nine days. This loss of spotter aircraft coverage severely hampered Omega Protein's ability to locate menhaden fish during this nine-day period and thereby reduced its amount of saleable product.

Unfavorable publicity or consumer perception of Cyvex's products could cause fluctuations in its operating results and could have a material adverse effect on its reputation, the demand for its products, and its ability to generate revenues. The Company is dependent upon consumer perception of the safety and quality of Cyvex's products, as well as similar products distributed by other companies. Consumer perception of

products can be significantly influenced by scientific research or findings, national media attention, and other publicity about product use. A product may be received favorably, resulting in high sales associated with that product that may not be sustainable as consumer preferences change. Future scientific research or publicity could be unfavorable to Cyvex's industry or any of its particular products and may not be consistent with earlier favorable research or publicity. Adverse publicity in the form of published scientific research or otherwise, whether or not accurate, that associates consumption of our products or any other similar products with illness or other adverse effects, that questions the benefits of Cyvex products or similar products, or that claims that such products are ineffective could have a material adverse effect on our reputation, the demand for Cyvex products, and its ability to generate revenues.

Compliance with new and existing governmental regulations could increase the Company's costs significantly and adversely affect Cyvex results of operations. The processing, formulation, manufacturing, packaging, labeling, advertising, and distribution of Cyvex products are subject to federal laws and regulation by one or more federal agencies, including the FDA, FTC, the Consumer Product Safety Commission, the United States Department of Agriculture, and the Environmental Protection Agency. These activities are also regulated by various state, local, and international laws and agencies of the states and localities in which our products are sold. Government regulations may prevent or delay the introduction, or require the reformulation, or require the discontinuance of Cyvex products, which could result in lost revenues and increased costs to us. For instance, the FDA regulates, among other things, the composition, safety, labeling, and marketing of dietary supplements (including vitamins, minerals, herbs, and other dietary ingredients for human use). The FDA may not accept the evidence of safety for any new dietary ingredient that Cyvex may wish to market, may determine that a particular dietary supplement or ingredient presents an unacceptable health risk, and may determine that a particular claim or statement of nutritional value that we use to support the marketing of a dietary supplement is an impermissible drug claim, the claim is not substantiated, or is an unauthorized version of a "health claim." Any of these actions could prevent Cyvex from marketing particular dietary supplement ingredients or making certain claims or statements with respect to those products. The FDA could also require Cyvex to remove a particular product from the market. Any future recall or removal would result in additional costs to the Company, including lost revenues from any products that Cyvex is required to remove from the market. Any product recalls or removals could also lead to liability, substantial costs, and reduced growth prospects.

Additional or more stringent regulations of dietary supplements and other products have been considered from time to time. These developments could require reformulation of some products to meet new standards, recalls or discontinuance of some products not able to be reformulated, additional record-keeping requirements, increased documentation of the properties of some products, additional or different labeling, additional scientific substantiation, adverse event reporting, or other new requirements. Any of these developments could increase our costs significantly. We may not be able to comply with the new rules without incurring additional expenses, which could be significant.

References

- Au, S.-Y., Qiu, B., & Wu, S.-Y. (Jennifer). (2020). *Do Risk Factor Disclosures Reduce Stock Price Crash Risk?* (SSRN Scholarly Paper ID 3363912). Social Science Research Network. <https://doi.org/10.2139/ssrn.3363912>
- Autore, D. M., Hutton, I., Peterson, D. R., & Smith, A. H. (2014). The effect of securities litigation on external financing. *Journal of Corporate Finance*, 27, 231–250. <https://doi.org/10.1016/j.jcorpfin.2014.05.007>
- Balakrishnan, K., & Bartov, E. (2011). *Analysts' Use of Qualitative Earnings Information: Evidence from the IPO Prospectus's Risk Factors Section*. 65.
- Bao, Y., & Datta, A. (2014). Simultaneously Discovering and Quantifying Risk Types from Textual Risk Disclosures. *Management Science*, 60(6), 1371–1391. <https://doi.org/10.1287/mnsc.2014.1930>
- Beatty, A., Cheng, L., & Zhang, H. (2019). Are Risk Factor Disclosures Still Relevant? Evidence from Market Reactions to Risk Factor Disclosures Before and After the Financial Crisis. *Contemporary Accounting Research*, 36(2), 805–838. <https://doi.org/10.1111/1911-3846.12444>
- Berkman, O. (2018). *Disclosure Effectiveness Weakened By Complicated Ownership*. <https://www.digitalistmag.com/finance/2018/02/19/disclosure-effectiveness-weakened-by-complicated-ownership-05813169/>
- Bonsall, S. B., Leone, A. J., Miller, B. P., & Rennekamp, K. (2017). A plain English measure of financial reporting readability. *Journal of Accounting and Economics*, 63(2), 329–357. <https://doi.org/10.1016/j.jacceco.2017.03.002>
- Bourveau, T., Lou, Y., & Wang, R. (2018). Shareholder Litigation and Corporate Disclosure: Evidence from Derivative Lawsuits. *Journal of Accounting Research*, 56(3), 797–842. <https://doi.org/10.1111/1475-679X.12191>

- Bushee, B. J., Gow, I. D., & Taylor, D. J. (2018). Linguistic Complexity in Firm Disclosures: Obfuscation or Information? *Journal of Accounting Research*, 56(1), 85–121. <https://doi.org/10.1111/1475-679X.12179>
- Callen, J. L., & Fang, X. (2015). Short interest and stock price crash risk. *Journal of Banking & Finance*, 60, 181–194. <https://doi.org/10.1016/j.jbankfin.2015.08.009>
- Campbell, J. L., Cecchini, M., Cianci, A. M., Ehinger, A. C., & Werner, E. M. (2019). Tax-related mandatory risk factor disclosures, future profitability, and stock returns. *Review of Accounting Studies*, 24(1), 264–308. <https://doi.org/10.1007/s11142-018-9474-y>
- Campbell, J. L., Chen, H., Dhaliwal, D. S., Lu, H., & Steele, L. B. (2014). The information content of mandatory risk factor disclosures in corporate filings. *Review of Accounting Studies*, 19(1), 396–455. <https://doi.org/10.1007/s11142-013-9258-3>
- Cao, Z., & Narayanamoorthy, G. S. (2011). The Effect of Litigation Risk on Management Earnings Forecasts*. *Contemporary Accounting Research*, 28(1), 125–173. <https://doi.org/10.1111/j.1911-3846.2010.01045.x>
- Cazier, R. A., McMullin, J. L., & Treu, J. S. (2020). Are Lengthy and Boilerplate Risk Factor Disclosures Inadequate? An Examination of Judicial and Regulatory Assessments of Risk Factor Language. *The Accounting Review*, TAR-2018-0657. <https://doi.org/10.2308/TAR-2018-0657>
- Chiu, T.-T., Guan, Y., & Kim, J.-B. (2018). The Effect of Risk Factor Disclosures on the Pricing of Credit Default Swaps. *Contemporary Accounting Research*, 35(4), 2191–2224. <https://doi.org/10.1111/1911-3846.12362>
- Donelson, D. C., McInnis, J. M., Mergenthaler, R. D., & Yu, Y. (2012). The Timeliness of Bad Earnings News and Litigation Risk. *The Accounting Review*, 87(6), 1967–1991. <https://doi.org/10.2308/accr-50221>

- Dong, H., & Zhang, H. (2019). Litigation Risk and Corporate Voluntary Disclosure: Evidence from Two Quasi-Natural Experiments. *European Accounting Review*, 28(5), 873–900. <https://doi.org/10.1080/09638180.2018.1559071>
- EY. (2014). *Disclosure effectiveness – What investors, company executives and other stakeholders are saying*. <https://www.eyjapan.jp/library/issue/us/gAAP-weekly-update/pdf/GAAP-2014-11-25-03.pdf>
- EY. (2017). *PACESETTERS IN FINANCIAL REPORTING Takeaways from the 2017 conference hosted by Pace University, FEI and EY*. 12.
- EY & FERF. (2015). *Disclosure effectiveness: Companies embrace the call to action*. 42.
- Filzen, J. J. (2015). The Information Content of Risk Factor Disclosures in Quarterly Reports. *Accounting Horizons*, 29(4), 887–916. <https://doi.org/10.2308/acch-51175>
- Garfinkel, J. A. (2009). Measuring Investors' Opinion Divergence. *Journal of Accounting Research*, 47(5), 1317–1348. <https://doi.org/10.1111/j.1475-679X.2009.00344.x>
- Gaulin, M. P. (2017). *Risk Fact or Fiction: The Information Content of Risk Factor Disclosures* [Thesis]. <https://scholarship.rice.edu/handle/1911/96089>
- Hope, O.-K., Hu, D., & Lu, H. (2016). The benefits of specific risk-factor disclosures. *Review of Accounting Studies*, 21(4), 1005–1045. <https://doi.org/10.1007/s11142-016-9371-1>
- Hopkins, J. (2018). Do Securities Class Actions Deter Misreporting? *Contemporary Accounting Research*, 35(4), 2030–2057. <https://doi.org/10.1111/1911-3846.12367>
- Houston, J. F., Lin, C., Liu, S., & Wei, L. (2019). Litigation Risk and Voluntary Disclosure: Evidence from Legal Changes. *The Accounting Review*, 94(5), 247–272. <https://doi.org/10.2308/accr-52355>
- Huang, A., Hui, K. W., & Li, R. Z. (2019). Federal Judge Ideology: A New Measure of Ex Ante Litigation Risk. *Journal of Accounting Research*, 57(2), 431–489. <https://doi.org/10.1111/1475-679X.12260>

- Huang, A., Shen, J., & Zang, A. Y. (2021). The unintended benefit of the risk factor mandate of 2005. *Review of Accounting Studies*. <https://doi.org/10.1007/s11142-021-09590-z>
- Johnson, M. F., Kasznik, R., & Nelson, K. K. (2001). The Impact of Securities Litigation Reform on the Disclosure of Forward-Looking Information By High Technology Firms. *Journal of Accounting Research*, 39(2), 297–327. <https://doi.org/10.1111/1475-679X.00014>
- Kim, I., & Skinner, D. J. (2012). Measuring securities litigation risk. *Journal of Accounting and Economics*, 53(1), 290–310. <https://doi.org/10.1016/j.jacceco.2011.09.005>
- Kravet, T., & Muslu, V. (2013). Textual risk disclosures and investors' risk perceptions. *Review of Accounting Studies*, 4(18), 1088–1122. <https://doi.org/10.1007/s11142-013-9228-9>
- Levy, H., Shalev, R., & Zur, E. (2018). The Effect of CFO Personal Litigation Risk on Firms' Disclosure and Accounting Choices. *Contemporary Accounting Research*, 35(1), 434–463. <https://doi.org/10.1111/1911-3846.12378>
- Loughran, T., & McDonald, B. (2011). When Is a Liability Not a Liability? Textual Analysis, Dictionaries, and 10-Ks. *The Journal of Finance*, 66(1), 35–65. <https://doi.org/10.1111/j.1540-6261.2010.01625.x>
- Loughran, T., & McDonald, B. (2014). Measuring Readability in Financial Disclosures. *The Journal of Finance*, 69(4), 1643–1671. <https://doi.org/10.1111/jofi.12162>
- Nelson, K. K., & Pritchard, A. C. (2016). Carrot or Stick? The Shift from Voluntary to Mandatory Disclosure of Risk Factors. *Journal of Empirical Legal Studies*, 13(2), 266–297. <https://doi.org/10.1111/jels.12115>
- Rogers, J. L., & Van Buskirk, A. (2009). Shareholder litigation and changes in disclosure behavior. *Journal of Accounting and Economics*, 47(1), 136–156. <https://doi.org/10.1016/j.jacceco.2008.04.003>

Rogers, J. L., Van Buskirk, A., & Zechman, S. L. C. (2011). Disclosure Tone and Shareholder Litigation. *The Accounting Review*, 86(6), 2155–2183. <https://doi.org/10.2308/accr-10137>

White, M. J. (2013). *The Path Forward on Disclosure*. SEC. <https://www.sec.gov/news/speech/spch101513mjw>

TABLE 1: SAMPLE SELECTION

Particulars	Observations	
Item 1A downloaded from Calcbench (Years 2008-19)		82150
Exclude:		
Forms other than 10-K & 20-F	330	
Disclosures containing < 100 words	9316	
Multiple filings for the same year	3664	
Duplicates	34	13344
Remaining disclosures from Calcbench data		68806
Exclude further:		
Financial years before 2009 and after 2018	9909	
Observations for which corresponding compustat data not found	15667	
Observations for which HQ states not found in LM's header file	490	
Observations for which HQ states are blank or foreign	4048	
Observations for which control variables not found	18686	
Singleton observations	244	49044
Remaining observations used in analysis		19762

TABLE 2: SUMMARY STATISTICS

VARIABLES	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)	(13) Difference significance
	N	mean	p25	p50	p75	sd	N	mean	p25	p50	p75	sd	
<u>Risk Factor Disclosure Characteristics</u>													
Avg_SentLength	10,012	33.558	31.028	33.479	35.881	4.011	9,750	34.768	32.153	34.530	37.040	5.869	***
Unique_Vocab	10,012	1203.112	880.000	1168.000	1475.000	438.287	9,750	1381.338	1067.000	1351.000	1676.000	464.530	***
Type Token Ratio	10,012	0.165	0.129	0.158	0.193	0.054	9,750	0.147	0.113	0.139	0.168	0.050	***
<u>Litigation Risk Measure</u>													
Liberal_Court	10,012	0.244	0.176	0.247	0.332	0.116	9,750	0.636	0.581	0.668	0.704	0.084	***
<u>Controls</u>													
Firm_Age	10,012	27.637	13.000	22.000	41.000	18.275	9,750	23.429	11.000	19.000	30.000	16.474	***
Avg_Accruals	10,012	0.113	0.032	0.057	0.098	1.786	9,750	0.102	0.034	0.064	0.117	0.154	
BigN	10,012	0.778	1.000	1.000	1.000	0.416	9,750	0.735	0.000	1.000	1.000	0.441	***
BTM	10,012	0.508	0.245	0.431	0.696	1.351	9,750	0.463	0.193	0.374	0.645	0.771	***
Income	10,012	285.081	-2.021	30.388	162.638	1468.654	9,750	337.187	-12.655	12.584	120.911	2000.956	**
Leverage	10,012	0.231	0.019	0.196	0.341	0.252	9,750	0.204	0.000	0.148	0.320	0.239	***
Size	10,012	6.894	5.559	6.963	8.235	2.000	9,750	6.708	5.229	6.705	8.100	2.126	***
Loss	10,012	0.274	0.000	0.000	1.000	0.446	9,750	0.369	0.000	0.000	1.000	0.483	***
Abn_Return	10,012	0.001	-0.012	0.000	0.011	0.045	9,750	0.000	-0.013	0.000	0.012	0.045	
Stderet	10,012	0.024	0.014	0.020	0.029	0.017	9,750	0.027	0.016	0.023	0.033	0.019	***
Beta	10,012	1.127	0.798	1.104	1.440	0.524	9,750	1.105	0.792	1.096	1.410	0.534	***
Returns Skewness	10,012	0.287	-0.303	0.166	0.684	1.565	9,750	0.393	-0.311	0.239	0.871	1.850	***
ROA	10,012	0.008	-0.009	0.038	0.077	1.763	9,750	-0.072	-0.068	0.027	0.071	0.381	***
Sh_Turn	10,012	0.906	0.419	0.690	1.100	1.132	9,750	1.022	0.426	0.730	1.206	1.304	***
Ln_RFDLength	10,012	8.640	8.210	8.682	9.097	0.679	9,750	8.898	8.527	8.945	9.347	0.665	***
ZScore	10,012	16.147	1.716	3.170	5.152	670.308	9,750	3.816	1.344	3.140	5.265	13.398	*
Lit_Risk KS	10,012	0.033	0.020	0.028	0.039	0.018	9,750	0.035	0.021	0.030	0.044	0.022	***

<u>Bid-ask spread</u>													
Spread [0,3]	9,700	0.418	0.036	0.079	0.260	1.040	9,377	0.480	0.040	0.103	0.375	1.099	***
Spread [0,5]	9,700	0.415	0.035	0.078	0.255	1.016	9,377	0.479	0.040	0.104	0.373	1.071	***
Spread [0,7]	9,700	0.413	0.035	0.078	0.255	1.011	9,377	0.474	0.040	0.102	0.373	1.036	***
<u>MD&A disclosure characteristics</u>													
MD&A Avg_SentLength	9,678	40.324	36.716	39.699	43.154	8.775	9,384	40.820	37.251	40.165	43.228	10.994	***
MD&A Unique_Vocab	9,678	1,252.492	1,059.000	1,238.500	1,426.000	319.074	9,384	1,244.634	1,062.000	1,236.000	1,413.000	303.451	*
MD&A Type Token Ratio	9,546	0.052	0.040	0.050	0.060	0.021	9,275	0.052	0.040	0.050	0.060	0.020	*
Ln_MD&ALength	8,758	9.188	8.925	9.230	9.517	0.575	8,688	9.167	8.909	9.211	9.479	0.525	***
<u>Partitioning variables</u>													
Negative Cash Flow from Operations	10,012	0.140	0.000	0.000	0.000	0.347	9,750	0.236	0.000	0.000	0.000	0.425	***
Low ROA	10,012	0.464	0.000	0.000	1.000	0.499	9,750	0.537	0.000	1.000	1.000	0.499	***
Fall in Earnings	10,012	0.422	0.000	0.000	1.000	0.494	9,750	0.438	0.000	0.000	1.000	0.496	**
High Litigation Risk (Kim & Skinner)	10,012	0.482	0.000	0.000	1.000	0.500	9,750	0.519	0.000	1.000	1.000	0.500	***
High Short Interest	9,874	0.483	0.000	0.000	1.000	0.500	9,648	0.517	0.000	1.000	1.000	0.500	***
Young Firm	10,012	0.476	0.000	0.000	1.000	0.499	9,750	0.580	0.000	1.000	1.000	0.494	***
Early Tenure CEO	6,150	0.526	0.000	1.000	1.000	0.499	5,332	0.471	0.000	0.000	1.000	0.499	***
CEO Change	10,012	0.065	0.000	0.000	0.000	0.246	9,750	0.051	0.000	0.000	0.000	0.221	***
<u>Industry Demeaned Dependent Variables</u>													
Avg_SentLength	10,012	-0.499	-2.887	-0.520	1.686	3.840	9,750	0.512	-1.921	0.365	2.629	5.719	***
Unique_Vocab	10,012	-72.607	-349.211	-91.311	186.865	400.895	9,750	74.558	-206.000	63.669	346.398	419.999	***
Type Token Ratio	10,012	0.007	-0.027	-0.000	0.032	0.050	9,750	-0.007	-0.038	-0.015	0.012	0.045	***

Notes: All variables are defined in Appendix A. This table provides descriptive statistics for all the variables used. The sample is partitioned by median of liberal_court values.

*, **, *** Denote statistical significance at 10 percent, 5 percent, and 1 percent levels, respectively (two-tailed tests).

TABLE 3: LITIGATION RISK AND RISK FACTOR DISCLOSURE COMPLEXITY

$$RFD_complexity_{(i,t)} = \beta_0 + \beta_1 Liberal_court_{(i,t)} + \sum_{k=2}^{18} \beta_k Controls_{(i,t)} + IndustryFE + YearFE + \varepsilon$$

VARIABLES	(1) Avg_ SentLength	(2) Avg_ SentLength	(3) Unique_Vocab	(4) Unique_Vocab	(5) Type Token Ratio	(6) Type Token Ratio
Liberal_Court	1.543*** [3.62]	1.359*** [3.26]	39.645*** [3.87]	36.710*** [3.72]	0.003*** [2.97]	0.003*** [2.59]
Firm_Age	-0.004 [-0.65]	-0.005 [-0.72]	-0.482** [-2.58]	-0.897*** [-4.19]	-0.000*** [-2.99]	-0.000*** [-4.20]
Avg_Accruals	0.033 [0.76]	-0.018 [-0.28]	3.899 [0.97]	0.863 [0.35]	0.001 [1.46]	0.000 [0.93]
BigN	0.072 [0.44]	0.150 [0.92]	4.607 [0.79]	13.168** [2.08]	0.000 [0.77]	0.001** [1.98]
BTM	-0.046* [-1.77]	-0.026 [-0.98]	1.071 [1.29]	1.723* [1.66]	0.000 [1.35]	0.000 [1.52]
Income	0.000 [0.37]	0.000 [0.36]	0.000 [0.27]	0.000 [0.07]	0.000 [0.88]	0.000 [0.73]
Leverage	0.935*** [3.55]	0.856*** [2.89]	-2.373 [-0.31]	-14.774* [-1.89]	0.001 [0.71]	-0.001 [-1.42]
Size	0.352*** [5.97]	0.304*** [5.26]	6.384*** [4.41]	3.235** [2.22]	0.001*** [3.28]	0.000 [1.50]
Loss	0.453*** [3.63]	0.353*** [2.96]	22.872*** [5.21]	15.812*** [4.36]	0.002*** [4.47]	0.001*** [3.77]
Abn_Return	-0.218 [-0.33]	-0.491 [-0.76]	42.344** [2.10]	26.483 [1.41]	0.003* [1.75]	0.002 [0.91]
Stderet	18.827*** [4.95]	14.127*** [3.73]	576.902*** [4.06]	361.726*** [2.76]	0.053*** [3.65]	0.034** [2.53]
Beta	-0.383*** [-3.59]	-0.345*** [-3.21]	2.197 [0.71]	4.980 [1.43]	0.000 [1.10]	0.000 [1.19]
Returns Skewness	-0.032* [-1.92]	-0.021 [-1.20]	-2.112*** [-3.43]	-1.188** [-2.08]	-0.000** [-2.45]	-0.000 [-1.07]
ROA	-0.097** [-2.14]	-0.033 [-0.51]	-3.712 [-1.00]	0.293 [0.12]	-0.000 [-1.02]	0.000 [0.12]
Sh_Turn	-0.047 [-1.17]	-0.044 [-1.20]	2.526 [1.11]	1.047 [0.50]	0.000 [1.23]	0.000 [0.63]
Ln_RFDLength	2.626*** [10.64]	2.325*** [7.43]	630.224*** [51.87]	609.445*** [45.21]	-0.077*** [-59.81]	-0.078*** [-53.78]
ZScore	0.000*** [12.41]	0.000*** [5.90]	-0.010* [-1.94]	-0.013*** [-5.01]	-0.000*** [-4.43]	-0.000*** [-9.34]
Lit_Risk KS	1.116 [0.43]	3.943 [1.39]	56.116 [0.68]	533.404*** [5.04]	-0.004 [-0.48]	0.041*** [4.00]
Constant	7.719*** [3.75]	10.750*** [4.06]	-4,315.125*** [-41.67]	-4,113.604*** [-35.09]	0.820*** [74.61]	0.838*** [65.52]
Observations	19,762	19,762	19,762	19,762	19,762	19,762
Adjusted R-squared	0.184	0.206	0.933	0.939	0.945	0.950
SIC2 FE	No	Yes	No	Yes	No	Yes
Year FE	No	Yes	No	Yes	No	Yes
Cluster	Firm	Firm	Firm	Firm	Firm	Firm

Notes: All variables are defined in Appendix A. Standard errors are clustered by firm.

*, **, *** Denote statistical significance at 10 percent, 5 percent, and 1 percent levels, respectively (two-tailed tests). Robust T-statistics are shown in parentheses.

This table presents the results of the main tests of risk factor disclosure complexity and litigation risk, run with and without fixed effects. Results in odd numbered columns are from regressions that do not incorporate fixed effects, while results in even numbered columns are from regressions that do. The dependent variable in columns (1) and (2) is the average sentence length of the risk factor disclosure, the dependent variable in columns (3) and (4) is the number of unique words from LM Master dictionary used in the disclosure, and the dependent variable in columns (5) and (6) is the Type Token Ratio of the risk factor disclosure. The main variable of interest is *Liberal_court*, which is a proxy for litigation risk based on judge ideology.

TABLE 4: LITIGATION RISK–RISK FACTOR DISCLOSURE COMPLEXITY ASSOCIATION FOR POOR PERFORMANCE FIRM-YEARS

$$RFD_complexity_{i,t} = \beta_0 + \beta_1 Liberal_court_{i,t} * Poor\ Performance_{i,t} + \beta_2 Poor\ Performance_{i,t} + \beta_3 Liberal_court_{i,t} + \sum_{k=4}^{20} \beta_k Controls_{i,t} + IndustryFE + YearFE + \varepsilon$$

VARIABLES	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
	Poor Performance = Negative Cash Flow from Operations			Poor Performance = Low ROA			Poor Performance = Fall in Earnings		
	Avg_Sent Length	Unique_Vocab	Type Token Ratio	Avg_Sent Length	Unique_Vocab	Type Token Ratio	Avg_Sent Length	Unique_Vocab	Type Token Ratio
Liberal Court * Poor Performance	-0.060 [-0.11]	69.336*** [3.58]	0.004** [2.40]	0.020 [0.04]	66.444*** [5.15]	0.005*** [3.28]	0.130 [0.45]	13.430** [2.12]	0.001* [1.78]
Poor Performance	0.221 [0.85]	-27.827*** [-2.90]	-0.002** [-2.33]	0.133 [0.51]	-19.504*** [-3.16]	-0.001 [-1.28]	-0.026 [-0.23]	-2.913 [-0.97]	-0.000 [-0.42]
Liberal_Court	1.356*** [2.90]	24.616** [2.41]	0.002* [1.76]	1.349** [2.23]	4.678 [0.43]	0.000 [0.32]	1.305*** [2.80]	31.064*** [3.06]	0.002** [2.03]
Lit_Risk KS	3.952 [1.40]	541.371*** [5.13]	0.041*** [4.05]	3.804 [1.35]	529.282*** [5.07]	0.040*** [3.98]	3.903 [1.38]	529.563*** [5.00]	0.041*** [3.94]
Firm_Age	-0.004 [-0.69]	-0.895*** [-4.18]	-0.000*** [-4.22]	-0.005 [-0.73]	-0.892*** [-4.16]	-0.000*** [-4.20]	-0.005 [-0.72]	-0.899*** [-4.20]	-0.000*** [-4.22]
Avg_Accruals	-0.029 [-0.43]	0.012 [0.01]	0.000 [0.88]	-0.022 [-0.33]	0.167 [0.08]	0.000 [0.74]	-0.020 [-0.31]	0.630 [0.27]	0.000 [0.84]
BigN	0.153 [0.93]	13.479** [2.13]	0.001** [2.00]	0.144 [0.88]	12.641** [2.02]	0.001* [1.92]	0.150 [0.91]	13.155** [2.08]	0.001** [1.98]
BTM	-0.025 [-0.92]	1.832* [1.67]	0.000 [1.54]	-0.029 [-1.13]	1.713* [1.66]	0.000 [1.50]	-0.026 [-0.99]	1.699* [1.66]	0.000 [1.52]
Income	0.000 [0.33]	0.000 [0.05]	0.000 [0.75]	0.000 [0.37]	0.000 [0.24]	0.000 [0.83]	0.000 [0.36]	0.000 [0.10]	0.000 [0.76]
Leverage	0.871*** [2.94]	-14.305* [-1.83]	-0.001 [-1.43]	0.838*** [2.83]	-15.126* [-1.93]	-0.001 [-1.52]	0.856*** [2.89]	-14.761* [-1.89]	-0.001 [-1.41]
Size	0.309*** [5.29]	3.321** [2.26]	0.000 [1.45]	0.309*** [5.34]	3.558** [2.46]	0.000* [1.74]	0.304*** [5.25]	3.229** [2.22]	0.000 [1.50]
Loss	0.299*** [2.64]	13.995*** [4.01]	0.001*** [3.95]	0.264** [2.14]	8.838** [2.50]	0.001 [1.57]	0.343*** [2.72]	14.896*** [3.94]	0.001*** [3.30]

Abn_Return	-0.462 [-0.72]	26.723 [1.42]	0.001 [0.88]	-0.473 [-0.73]	27.211 [1.44]	0.002 [0.97]	-0.484 [-0.74]	27.212 [1.45]	0.002 [0.96]
Stderet	13.462*** [3.52]	343.282*** [2.65]	0.034** [2.58]	14.057*** [3.71]	372.002*** [2.85]	0.034*** [2.58]	14.169*** [3.76]	365.702*** [2.80]	0.034*** [2.58]
Beta	-0.344*** [-3.21]	4.654 [1.35]	0.000 [1.13]	-0.349*** [-3.24]	4.701 [1.35]	0.000 [1.10]	-0.344*** [-3.21]	5.014 [1.44]	0.000 [1.20]
Returns Skewness	-0.020 [-1.15]	-1.175** [-2.06]	-0.000 [-1.09]	-0.020 [-1.16]	-1.182** [-2.08]	-0.000 [-1.04]	-0.020 [-1.14]	-1.128** [-1.97]	-0.000 [-0.92]
ROA	-0.017 [-0.25]	1.315 [0.64]	0.000 [0.26]	-0.027 [-0.42]	1.208 [0.57]	0.000 [0.52]	-0.030 [-0.46]	0.559 [0.24]	0.000 [0.26]
Sh_Turn	-0.044 [-1.19]	1.029 [0.49]	0.000 [0.62]	-0.043 [-1.17]	1.034 [0.49]	0.000 [0.64]	-0.044 [-1.20]	1.036 [0.49]	0.000 [0.62]
Ln_RFDLength	2.319*** [7.41]	609.390*** [45.17]	-0.078*** [-53.73]	2.316*** [7.37]	609.122*** [44.98]	-0.078*** [-53.51]	2.325*** [7.43]	609.453*** [45.20]	-0.078*** [-53.78]
ZScore	0.000*** [5.14]	-0.013*** [-6.45]	-0.000*** [-9.93]	0.000*** [5.69]	-0.013*** [-6.55]	-0.000*** [-12.16]	0.000*** [5.87]	-0.013*** [-5.21]	-0.000*** [-9.79]
Constant	10.765*** [4.08]	-4,108.977*** [-35.05]	0.838*** [65.56]	10.776*** [4.12]	-4,101.621*** [-34.92]	0.839*** [65.58]	10.764*** [4.09]	-4,112.116*** [-35.01]	0.838*** [65.45]
Observations	19,762	19,762	19,762	19,762	19,762	19,762	19,762	19,762	19,762
Adjusted R-squared	0.207	0.940	0.950	0.207	0.940	0.950	0.206	0.939	0.950
SIC2 FE	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Year FE	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Cluster	Firm	Firm	Firm	Firm	Firm	Firm	Firm	Firm	Firm

Notes: All variables are defined in Appendix A. Standard errors are clustered by firm.

*, **, *** Denote statistical significance at 10 percent, 5 percent, and 1 percent levels, respectively (two-tailed tests). Robust T-statistics are shown in parentheses.

This table presents the results of the main tests from Table 3 to observe the variation between firm-years that exhibit poor firm performance, and those that do not. Columns (1) to (3) use negative cash flow from operations as an indicator of poor performance, columns (4) to (6) use below median return on assets as a proxy for poor performance, and columns (7) to (9) use a decrease in income before extraordinary items as an indicator of poor performance. The dependent variable in columns (1), (4) & (7) is the average sentence length of the risk factor disclosure, the dependent variable in columns (2), (5) and (8) is the number of unique words from LM Master dictionary used in the disclosure, and the dependent variable in columns (3), (6) and (9) is the Type Token Ratio of the risk factor disclosure. The main variable of interest is *Liberal Court * Poor Performance* which is an interaction of *Liberal court*, our measure of litigation risk, and *Poor Performance*, an indicator variable that takes value 1 for negative cash flow from operations (Columns (1) to (3)), below median return on assets (Columns (4) to (6)), and decrease in income before extraordinary items (Columns (7) to (9)). All tests include industry fixed effects and year fixed effects.

TABLE 5: LITIGATION RISK–RISK FACTOR DISCLOSURE COMPLEXITY ASSOCIATION FOR OTHER BAD NEWS FIRM-YEARS

$$RFD_complexity_{i,t} = \beta_0 + \beta_1 Liberal_court_{i,t} * Bad\ News_{i,t} + \beta_2 Bad\ News_{i,t} + \beta_3 Liberal_court_{i,t} + \sum_{k=4}^{20} \beta_k Controls_{i,t} + IndustryFE + YearFE + \varepsilon$$

VARIABLES	(1)	(2)	(3)	(4)	(5)	(6)
	Bad News = High Litigation Risk (Kim & Skinner) Avg_Sent Length	High Litigation Risk (Kim & Skinner) Unique_Vocab	High Litigation Risk (Kim & Skinner) Type Token Ratio	Bad News = High Short Interest Avg_Sent Length	High Short Interest Unique_Vocab	High Short Interest Type Token Ratio
Liberal Court *						
Bad News	0.508 [0.82]	78.229*** [5.26]	0.007*** [4.05]	0.373 [0.63]	50.447*** [3.62]	0.003** [2.31]
Bad News	-0.056 [-0.19]	-24.665*** [-3.44]	-0.003*** [-3.26]	-0.265 [-1.06]	-15.517** [-2.55]	-0.001* [-1.66]
Liberal_Court	1.119** [2.05]	-0.755 [-0.06]	-0.001 [-0.53]	1.197** [2.12]	13.451 [1.09]	0.001 [0.82]
Lit_Risk KS	1.625 [0.54]	379.436*** [3.68]	0.034*** [3.42]	4.358 [1.52]	543.530*** [5.10]	0.042*** [4.06]
Firm_Age	-0.005 [-0.72]	-0.884*** [-4.14]	-0.000*** [-4.15]	-0.005 [-0.83]	-0.879*** [-4.09]	-0.000*** [-4.20]
Avg_Accruals	-0.018 [-0.29]	0.892 [0.36]	0.000 [0.95]	-0.009 [-0.15]	0.814 [0.33]	0.000 [0.93]
BigN	0.146 [0.89]	12.676** [2.02]	0.001* [1.94]	0.142 [0.86]	13.825** [2.18]	0.001** [2.07]
BTM	-0.028 [-1.05]	1.647 [1.64]	0.000 [1.52]	-0.045* [-1.89]	1.483 [1.53]	0.000 [1.37]
Income	0.000 [0.38]	0.000 [0.08]	0.000 [0.71]	0.000 [0.32]	0.000 [0.25]	0.000 [0.77]
Leverage	0.863*** [2.92]	-13.711* [-1.77]	-0.001 [-1.30]	0.808*** [2.69]	-13.118* [-1.66]	-0.001 [-1.19]
Size	0.296*** [5.24]	2.843* [1.95]	0.000 [1.46]	0.309*** [5.34]	2.858* [1.93]	0.000 [1.37]
Loss	0.348*** [2.92]	15.567*** [4.32]	0.001*** [3.79]	0.347*** [2.95]	15.214*** [4.21]	0.001*** [3.69]
Abn_Return	-0.505 [-0.78]	24.285 [1.30]	0.001 [0.80]	-0.313 [-0.49]	24.004 [1.28]	0.001 [0.83]
Stderet	13.876*** [3.66]	349.388*** [2.68]	0.034** [2.52]	14.399*** [3.75]	385.334*** [2.87]	0.036*** [2.63]
Beta	-0.353*** [-3.33]	4.117 [1.19]	0.000 [1.01]	-0.332*** [-3.16]	4.420 [1.26]	0.000 [1.14]
Returns						
Skewness	-0.020 [-1.14]	-1.128** [-1.99]	-0.000 [-1.03]	-0.022 [-1.29]	-1.121** [-1.96]	-0.000 [-1.04]
ROA	-0.032 [-0.50]	0.252 [0.10]	0.000 [0.08]	-0.041 [-0.66]	0.401 [0.17]	0.000 [0.14]
Sh_Turn	-0.044 [-1.19]	1.129 [0.54]	0.000 [0.66]	-0.044 [-1.26]	0.446 [0.21]	0.000 [0.48]
Ln_RFDLength	2.318*** [7.33]	609.114*** [45.25]	-0.078*** [-53.90]	2.317*** [7.28]	607.427*** [44.78]	-0.079*** [-53.50]
ZScore	0.000*** [5.95]	-0.013*** [-4.87]	-0.000*** [-9.04]	0.000*** [5.88]	-0.013*** [-5.39]	-0.000*** [-9.87]
Constant	10.985***	-4,090.398***	0.840***	10.904***	-4,087.498***	0.840***

	[4.05]	[-34.56]	[64.83]	[4.04]	[-34.48]	[64.60]
Observations	19,762	19,762	19,762	19,522	19,522	19,522
Adjusted R-squared	0.207	0.940	0.950	0.205	0.940	0.950
SIC2 FE	Yes	Yes	Yes	Yes	Yes	Yes
Year FE	Yes	Yes	Yes	Yes	Yes	Yes
Cluster	Firm	Firm	Firm	Firm	Firm	Firm

Notes: All variables are defined in Appendix A. Standard errors are clustered by firm.

*, **, *** Denote statistical significance at 10 percent, 5 percent, and 1 percent levels, respectively (two-tailed tests). Robust T-statistics are shown in parentheses.

This table presents the results of the main tests from Table 3 to observe the variation between firm-years that had some kind of bad news which could be associated with higher likelihood of shareholder lawsuits and those that did not. Columns (1) to (3) use litigation risk measure created by Kim & Skinner (2012) as a proxy for bad news that makes a firm prone to shareholder lawsuits, and columns (4) to (6) use average short interest as a proxy for bad news. The dependent variable in columns (1) and (4) is the average sentence length of the risk factor disclosure, the dependent variable in columns (2) and (5) is the number of unique words from LM Master dictionary used in the disclosure, and the dependent variable in columns (3) and (6) is the Type Token Ratio of the risk factor disclosure. The main variable of interest is *Liberal Court * Bad News* which is an interaction of *Liberal court*, our measure of litigation risk, and *Bad News*, an indicator variable that takes value 1 for above median values of Kim & Skinner's litigation risk (Columns (1) to (3)) and above median average short interest (Columns (4) to (6)). All tests include industry fixed effects and year fixed effects.

TABLE 6: LITIGATION RISK–RISK FACTOR DISCLOSURE COMPLEXITY ASSOCIATION FOR EARLY-STAGE FIRMS AND CEOs

$$RFD_complexity_{i,t} = \beta_0 + \beta_1 Liberal_court_{i,t} * Early_Stage_{i,t} + \beta_2 Early_Stage_{i,t} + \beta_3 Liberal_court_{i,t} + \sum_{k=4}^{20} \beta_k Controls_{i,t} + IndustryFE + YearFE + \varepsilon$$

VARIABLES	Early Stage = Young Firm			Early Stage = Early Tenure CEO		
	Avg_Sent Length	Unique_Vocab	Type Token Ratio	Avg_Sent Length	Unique_Vocab	Type Token Ratio
Liberal Court *						
Early Stage	0.437 [0.76]	72.908*** [4.88]	0.006*** [3.38]	0.195 [0.27]	-8.244 [-0.49]	-0.002 [-0.85]
Early Stage	0.025 [0.09]	-26.042*** [-3.22]	-0.002** [-2.43]	-0.180 [-0.58]	-1.480 [-0.19]	0.000 [0.13]
Liberal_Court	1.141** [2.22]	0.572 [0.05]	-0.000 [-0.09]	1.202** [2.12]	25.648* [1.82]	0.002 [0.97]
Lit_Risk KS	3.940 [1.40]	525.569*** [4.97]	0.040*** [3.93]	0.501 [0.13]	312.522*** [3.27]	0.025** [2.38]
Firm_Age	-0.000 [-0.04]	-0.817*** [-4.01]	-0.000*** [-4.14]	0.001 [0.10]	-0.435*** [-2.89]	-0.000*** [-3.05]
Avg_Accruals	-0.023 [-0.35]	0.414 [0.18]	0.000 [0.84]	0.653 [0.57]	-11.161 [-0.64]	-0.002 [-1.30]
BigN	0.139 [0.86]	12.243** [1.96]	0.001* [1.92]	0.451* [1.82]	-10.999 [-1.44]	-0.001 [-0.86]
BTM	-0.026 [-0.97]	1.781* [1.67]	0.000 [1.53]	-0.175 [-1.30]	-1.455 [-0.56]	-0.000 [-0.97]
Income	0.000 [0.37]	0.000 [0.19]	0.000 [0.80]	-0.000 [-0.39]	0.000 [0.19]	0.000 [0.77]
Leverage	0.865*** [2.92]	-12.913 [-1.64]	-0.001 [-1.21]	0.404 [1.05]	-21.338** [-2.43]	-0.002* [-1.95]
Size	0.303*** [5.26]	3.283** [2.27]	0.000 [1.54]	0.495*** [5.85]	6.306*** [3.48]	0.000** [2.08]
Loss	0.344*** [2.91]	14.873*** [4.13]	0.001*** [3.61]	0.526*** [3.10]	7.974* [1.68]	0.001 [1.17]
Abn_Return	-0.494 [-0.77]	27.068 [1.44]	0.002 [0.94]	-1.095 [-0.83]	1.530 [0.07]	-0.001 [-0.36]
Stderet	13.894*** [3.70]	344.364*** [2.66]	0.033** [2.47]	29.342*** [3.75]	1.119 [0.01]	0.002 [0.13]
Beta	-0.344*** [-3.21]	4.787 [1.39]	0.000 [1.14]	-0.265* [-1.80]	1.662 [0.42]	-0.000 [-0.11]
Returns						
Skewness	-0.020 [-1.16]	-1.121** [-1.97]	-0.000 [-0.99]	-0.023 [-1.11]	0.392 [0.68]	0.000 [0.76]
ROA	-0.027 [-0.41]	0.734 [0.32]	0.000 [0.26]	0.716 [0.64]	-37.309 [-1.50]	-0.004* [-1.82]
Sh_Turn	-0.046 [-1.25]	0.891 [0.43]	0.000 [0.60]	-0.075 [-0.77]	-0.615 [-0.26]	-0.000 [-0.40]
Ln_RFDLength	2.308*** [7.23]	608.531*** [44.75]	-0.078*** [-53.38]	2.624*** [5.40]	630.303*** [74.80]	-0.076*** [-86.70]
ZScore	0.000*** [5.89]	-0.012*** [-5.15]	-0.000*** [-9.64]	-0.014 [-1.32]	0.097 [0.41]	-0.000 [-0.08]
Constant	10.793***	-4,094.595***	0.840***	6.061	-4,286.541***	0.820***

	[4.04]	[-35.07]	[65.51]	[1.54]	[-57.81]	[104.33]
Observations	19,762	19,762	19,762	11,482	11,482	11,482
Adjusted R-squared	0.207	0.940	0.950	0.158	0.949	0.954
SIC2 FE	Yes	Yes	Yes	Yes	Yes	Yes
Year FE	Yes	Yes	Yes	Yes	Yes	Yes
Cluster	Firm	Firm	Firm	Firm	Firm	Firm

Notes: All variables are defined in Appendix A. Standard errors are clustered by firm.

*, **, *** Denote statistical significance at 10 percent, 5 percent, and 1 percent levels, respectively (two-tailed tests). Robust T-statistics are shown in parentheses.

This table presents the results of the main tests from Table 3 to observe the variation between firm-years that represent firms/CEOs in their early stages and those that do not. Columns (1) to (3) run tests for firms that are younger in age, and columns (4) to (6) run tests for firms that have CEOs who are in their earlier years of their role. The dependent variable in columns (1) and (4) is the average sentence length of the risk factor disclosure, the dependent variable in columns (2) and (5) is the number of unique words from LM Master dictionary used in the disclosure, and the dependent variable in columns (3) and (6) is the Type Token Ratio of the risk factor disclosure. The main variable of interest is *Liberal Court * Early Stage* which is an interaction of *Liberal court*, our measure of litigation risk, and *Early Stage*, an indicator variable that takes value 1 for below median values of Firm Age (Columns (1) to (3)) and below median values of CEO Tenure (Columns (4) to (6)). All tests include industry fixed effects and year fixed effects.

TABLE 7: STOCK PRICE SPREADS AND RISK FACTOR DISCLOSURE COMPLEXITY

$$Bid_ask_spread_{i,t} = \beta_0 + \beta_1 RFD_complexity_{i,t} + \sum_{k=2}^{18} \beta_k Controls_{i,t} + IndustryFE + YearFE + \varepsilon$$

VARIABLES	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
	Spread [0,3]			Spread [0,5]			Spread [0,7]		
Avg_SentLength	0.006*			0.006*			0.007*		
	[1.91]			[1.84]			[1.81]		
Unique_Vocab		0.000***			0.000***			0.000***	
		[2.91]			[3.24]			[3.43]	
Type Token Ratio			2.680***			2.843***			2.983***
			[2.58]			[2.93]			[3.14]
Firm_Age	0.004***	0.004***	0.004***	0.004***	0.004***	0.004***	0.004***	0.004***	0.004***
	[5.69]	[5.90]	[5.88]	[5.73]	[6.00]	[5.97]	[5.62]	[5.94]	[5.90]
Avg_Accruals	-0.058**	-0.060**	-0.060**	-0.051*	-0.054*	-0.054*	-0.050*	-0.052*	-0.052*
	[-1.97]	[-2.07]	[-2.05]	[-1.83]	[-1.93]	[-1.90]	[-1.82]	[-1.93]	[-1.91]
BigN	-0.222***	-0.226***	-0.225***	-0.221***	-0.224***	-0.224***	-0.216***	-0.220***	-0.220***
	[-7.11]	[-7.16]	[-7.15]	[-7.35]	[-7.41]	[-7.40]	[-7.36]	[-7.43]	[-7.41]
BTM	0.040**	0.039**	0.039**	0.045***	0.044**	0.044**	0.042**	0.041**	0.041**
	[2.35]	[2.29]	[2.29]	[2.61]	[2.55]	[2.55]	[2.47]	[2.40]	[2.40]
Income	0.000***	0.000***	0.000***	0.000***	0.000***	0.000***	0.000***	0.000***	0.000***
	[4.71]	[4.65]	[4.64]	[4.71]	[4.64]	[4.64]	[4.74]	[4.67]	[4.66]
Leverage	0.117**	0.128***	0.125***	0.122***	0.133***	0.131***	0.127***	0.139***	0.136***
	[2.49]	[2.75]	[2.68]	[2.72]	[3.03]	[2.95]	[2.88]	[3.20]	[3.12]
Size	-0.180***	-0.180***	-0.180***	-0.180***	-0.179***	-0.179***	-0.180***	-0.179***	-0.179***
	[-16.11]	[-16.26]	[-16.22]	[-15.99]	[-16.12]	[-16.09]	[-16.34]	[-16.51]	[-16.47]
Loss	0.117***	0.114***	0.116***	0.106***	0.103***	0.104***	0.109***	0.106***	0.107***
	[5.51]	[5.34]	[5.42]	[5.06]	[4.91]	[5.00]	[5.27]	[5.12]	[5.21]
Abn_Return	-0.156	-0.167	-0.163	-0.177	-0.189	-0.185	-0.196	-0.208	-0.204
	[-0.88]	[-0.94]	[-0.92]	[-1.04]	[-1.11]	[-1.08]	[-1.21]	[-1.28]	[-1.25]
Stderet	15.092***	15.058***	15.083***	15.305***	15.278***	15.303***	14.820***	14.793***	14.817***
	[6.22]	[6.24]	[6.24]	[6.32]	[6.34]	[6.34]	[6.23]	[6.26]	[6.26]
Beta	-0.523***	-0.526***	-0.526***	-0.522***	-0.526***	-0.525***	-0.519***	-0.523***	-0.522***
	[-15.56]	[-15.67]	[-15.65]	[-16.26]	[-16.38]	[-16.37]	[-16.93]	[-17.05]	[-17.03]
Returns Skewness	-0.022***	-0.022***	-0.022***	-0.022***	-0.021***	-0.022***	-0.021***	-0.021***	-0.021***

	[-4.20]	[-4.19]	[-4.22]	[-4.13]	[-4.11]	[-4.15]	[-4.08]	[-4.06]	[-4.10]
ROA	0.054*	0.055**	0.055*	0.049*	0.050*	0.050*	0.047*	0.049*	0.048*
	[1.91]	[1.98]	[1.95]	[1.80]	[1.88]	[1.85]	[1.79]	[1.87]	[1.84]
Sh_Turn	-0.121***	-0.121***	-0.121***	-0.121***	-0.121***	-0.122***	-0.118***	-0.118***	-0.118***
	[-8.54]	[-8.55]	[-8.56]	[-8.72]	[-8.72]	[-8.73]	[-8.62]	[-8.62]	[-8.64]
Ln_RFDLength	-0.171***	-0.358***	0.052	-0.177***	-0.371***	0.061	-0.180***	-0.381***	0.069
	[-6.24]	[-4.13]	[0.72]	[-6.56]	[-4.54]	[0.90]	[-6.71]	[-4.75]	[1.06]
ZScore	0.000**	0.000***	0.000***	0.000**	0.000***	0.000***	0.000**	0.000***	0.000***
	[2.36]	[2.94]	[2.97]	[2.00]	[2.67]	[2.72]	[2.07]	[2.78]	[2.85]
Lit_Risk KS	3.546***	3.390***	3.458***	3.547***	3.387***	3.456***	3.511***	3.345***	3.414***
	[7.68]	[7.63]	[7.63]	[7.91]	[7.80]	[7.82]	[7.94]	[7.81]	[7.84]
Constant	3.164***	4.571***	0.974	3.176***	4.653***	0.858	3.201***	4.727***	0.767
	[14.08]	[7.43]	[1.21]	[14.36]	[7.98]	[1.15]	[14.46]	[8.26]	[1.05]
Observations	19,075	19,075	19,075	19,075	19,075	19,075	19,075	19,075	19,075
Adjusted R-squared	0.438	0.438	0.438	0.458	0.458	0.458	0.466	0.467	0.467
SIC2 FE	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Year FE	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Cluster	Firm	Firm	Firm	Firm	Firm	Firm	Firm	Firm	Firm

Notes: All variables are defined in Appendix A. Standard errors are clustered by firm.

*, **, *** Denote statistical significance at 10 percent, 5 percent, and 1 percent levels, respectively (two-tailed tests). Robust T-statistics are shown in parentheses.

This table presents the results of the regressions of stock price spreads on risk factor disclosure complexity. The dependent variable in the table is stock price spread for relative to 10-K filing date. The period for which stock price spread is calculated is [0,3], [0,5] and [0,7] days relative to 10-K filing date in columns (1) to (3), columns (4) to (6) and columns (7) to (9) respectively. The main variable of interest in columns (1), (4) and (7) is the average sentence length of the risk factor disclosure, while in columns (2), (5) and (8) is the number of unique words from LM Master dictionary used in the disclosure, and in columns (3), (6) and (9) is the Type Token Ratio of the risk factor disclosure. All tests include industry fixed effects and year fixed effects.

TABLE 8: PLACEBO – STOCK PRICE SPREADS AND MD&A COMPLEXITY

$$Spread_{i,t} = \beta_0 + \beta_1 MD\&A_complexity_{i,t} + \sum_{k=2}^{18} \beta_k Controls_{i,t} + IndustryFE + YearFE + \varepsilon$$

VARIABLES	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
	Spread [0,3]			Spread [0,5]			Spread [0,5]		
MD&A Avg_SentLength	-0.000 [-0.46]			-0.000 [-0.58]			-0.000 [-0.60]		
MD&A Unique_Vocab		0.000 [1.30]			0.000 [1.39]			0.000 [1.31]	
MD&A Type Token Ratio			1.231 [0.90]			1.089 [0.89]			0.905 [0.77]
Firm_Age	0.006*** [8.17]	0.006*** [8.03]	0.006*** [8.24]	0.006*** [8.40]	0.006*** [8.24]	0.006*** [8.46]	0.006*** [8.43]	0.006*** [8.28]	0.006*** [8.50]
Avg_Accruals	-0.076** [-2.41]	-0.077** [-2.45]	-0.077** [-2.42]	-0.073** [-2.38]	-0.074** [-2.42]	-0.073** [-2.37]	-0.070** [-2.39]	-0.071** [-2.43]	-0.071** [-2.38]
BigN	-0.221*** [-7.10]	-0.221*** [-7.09]	-0.224*** [-7.17]	-0.219*** [-7.30]	-0.219*** [-7.29]	-0.222*** [-7.37]	-0.215*** [-7.30]	-0.215*** [-7.29]	-0.218*** [-7.36]
BTM	0.044** [2.45]	0.043** [2.42]	0.048** [2.42]	0.048*** [2.68]	0.047*** [2.65]	0.052*** [2.68]	0.045** [2.54]	0.044** [2.51]	0.049** [2.50]
Income	0.000*** [4.72]	0.000*** [4.75]	0.000*** [5.01]	0.000*** [4.73]	0.000*** [4.77]	0.000*** [5.02]	0.000*** [4.76]	0.000*** [4.79]	0.000*** [5.04]
Leverage	0.150*** [3.11]	0.150*** [3.09]	0.152*** [3.07]	0.152*** [3.33]	0.151*** [3.31]	0.155*** [3.34]	0.157*** [3.48]	0.156*** [3.47]	0.161*** [3.51]
Size	-0.176*** [-15.20]	-0.177*** [-15.25]	-0.179*** [-15.30]	-0.176*** [-15.22]	-0.177*** [-15.28]	-0.178*** [-15.28]	-0.176*** [-15.60]	-0.177*** [-15.65]	-0.178*** [-15.63]
Loss	0.093*** [4.24]	0.092*** [4.17]	0.092*** [4.10]	0.083*** [3.86]	0.081*** [3.79]	0.082*** [3.75]	0.086*** [4.05]	0.084*** [3.98]	0.085*** [3.94]
Abn_Return	-0.100 [-0.56]	-0.098 [-0.55]	-0.112 [-0.63]	-0.134 [-0.79]	-0.132 [-0.77]	-0.143 [-0.83]	-0.158 [-0.98]	-0.156 [-0.96]	-0.166 [-1.02]
Stderet	15.347*** [5.97]	15.327*** [5.96]	15.299*** [5.88]	15.497*** [6.07]	15.476*** [6.06]	15.460*** [5.98]	15.010*** [5.97]	14.990*** [5.97]	14.983*** [5.89]
Beta	-0.544*** [-15.72]	-0.543*** [-15.59]	-0.544*** [-15.56]	-0.542*** [-16.43]	-0.541*** [-16.31]	-0.542*** [-16.26]	-0.540*** [-16.95]	-0.538*** [-16.82]	-0.540*** [-16.79]
Returns Skewness	-0.022***	-0.022***	-0.021***	-0.022***	-0.022***	-0.021***	-0.021***	-0.021***	-0.021***

	[-3.95]	[-3.96]	[-3.87]	[-3.99]	[-4.00]	[-3.93]	[-3.92]	[-3.93]	[-3.87]
ROA	0.072**	0.073**	0.072**	0.069**	0.070**	0.069**	0.067**	0.068**	0.067**
	[2.37]	[2.41]	[2.37]	[2.37]	[2.41]	[2.35]	[2.36]	[2.40]	[2.35]
Sh_Turn	-0.121***	-0.121***	-0.120***	-0.121***	-0.121***	-0.121***	-0.117***	-0.118***	-0.117***
	[-8.20]	[-8.21]	[-8.12]	[-8.37]	[-8.39]	[-8.30]	[-8.27]	[-8.28]	[-8.20]
Ln_MDNA Length	-0.118***	-0.160***	-0.077*	-0.115***	-0.160***	-0.080**	-0.112***	-0.153***	-0.082**
	[-4.15]	[-3.43]	[-1.84]	[-4.29]	[-3.51]	[-2.03]	[-4.31]	[-3.45]	[-2.17]
ZScore	0.000***	0.000***	0.000***	0.000**	0.000**	0.000**	0.000**	0.000**	0.000***
	[2.60]	[2.66]	[2.82]	[2.35]	[2.41]	[2.54]	[2.46]	[2.51]	[2.63]
Lit_Risk KS	2.766***	2.723***	2.792***	2.754***	2.709***	2.777***	2.694***	2.653***	2.723***
	[6.45]	[6.34]	[6.49]	[6.57]	[6.44]	[6.60]	[6.53]	[6.40]	[6.56]
Constant	2.911***	3.192***	2.480***	2.883***	3.175***	2.496***	2.853***	3.120***	2.534***
	[10.92]	[8.51]	[5.46]	[11.18]	[8.63]	[5.92]	[11.37]	[8.71]	[6.23]
Observations	18,401	18,401	18,166	18,401	18,401	18,166	18,401	18,401	18,166
Adjusted R-squared	0.433	0.433	0.433	0.452	0.452	0.452	0.460	0.460	0.460
SIC2 FE	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Year FE	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Cluster	Firm	Firm	Firm	Firm	Firm	Firm	Firm	Firm	Firm

Notes: All variables are defined in Appendix A. Standard errors are clustered by firm.

*, **, *** Denote statistical significance at 10 percent, 5 percent, and 1 percent levels, respectively (two-tailed tests). Robust T-statistics are shown in parentheses.

This table presents the results of a placebo test. I run the same regressions as in Table 4, but instead of using characteristics of risk factor disclosures, I change the dependent variables to the same characteristics of the Management Discussion and Analysis (MD&A) disclosure. The dependent variable in the table is stock price spread for relative to 10-K filing date. The period for which stock price spread is calculated is [0,3], [0,5] and [0,7] days relative to 10-K filing date in columns (1) to (3), columns (4) to (6) and columns (7) to (9) respectively. The main variable of interest in columns (1), (4) and (7) is the average sentence length of the MD&A, while in columns (2), (5) and (8) is the number of unique words from LM Master dictionary used in the MD&A, and in columns (3), (6) and (9) is the Type Token Ratio of the MD&A. All tests include industry fixed effects and year fixed effects.

TABLE 9: LITIGATION RISK–RISK FACTOR DISCLOSURE COMPLEXITY ASSOCIATION FOR CEO CHANGE YEARS

$$RFD_complexity_{i,t} = \beta_0 + \beta_1 Liberal_court_{i,t} * CEO\ Change_{i,t} + \beta_2 CEO\ Change_{i,t} + \beta_3 Liberal_court_{i,t} + \sum_{k=4}^{20} \beta_k Controls_{i,t} + IndustryFE + YearFE + \varepsilon$$

VARIABLES	(1) Avg_Sent Length	(2) Unique_Vocab	(3) Type Token Ratio
Liberal Court * CEO Change	0.248 [0.47]	-7.377 [-0.55]	-0.001 [-0.88]
CEO Change	-0.259 [-1.18]	-4.520 [-0.77]	0.000 [0.11]
Liberal_Court	1.341*** [3.13]	37.029*** [3.70]	0.003*** [2.63]
Firm_Age	-0.004 [-0.70]	-0.889*** [-4.16]	-0.000*** [-4.19]
Avg_Accruals	-0.017 [-0.27]	0.875 [0.35]	0.000 [0.93]
BigN	0.154 [0.94]	13.357** [2.11]	0.001** [2.00]
BTM	-0.026 [-0.98]	1.730* [1.66]	0.000 [1.52]
Income	0.000 [0.35]	0.000 [0.05]	0.000 [0.73]
Leverage	0.858*** [2.90]	-14.680* [-1.88]	-0.001 [-1.41]
Size	0.305*** [5.28]	3.295** [2.26]	0.000 [1.52]
Loss	0.356*** [2.98]	15.912*** [4.38]	0.001*** [3.78]
Abn_Return	-0.495 [-0.77]	26.358 [1.40]	0.002 [0.91]
Stderet	14.126*** [3.73]	361.931*** [2.77]	0.034** [2.53]
Beta	-0.346*** [-3.22]	4.913 [1.41]	0.000 [1.18]
Returns Skewness	-0.022 [-1.25]	-1.227** [-2.15]	-0.000 [-1.11]
ROA	-0.033 [-0.51]	0.293 [0.12]	0.000 [0.12]
Sh_Turn	-0.043 [-1.18]	1.073 [0.51]	0.000 [0.63]
Ln_RFDLength	2.326*** [7.43]	609.458*** [45.23]	-0.078*** [-53.79]
ZScore	0.000*** [5.86]	-0.013*** [-5.07]	-0.000*** [-9.41]
Lit_Risk KS	3.980 [1.40]	535.979*** [5.07]	0.041*** [4.01]
Constant	10.747*** [4.07]	-4,114.246*** [-35.10]	0.838*** [65.49]
Observations	19,762	19,762	19,762

Adjusted R-squared	0.206	0.939	0.950
SIC2 FE	Yes	Yes	Yes
Year FE	Yes	Yes	Yes
Cluster	Firm	Firm	Firm

Notes: All variables are defined in Appendix A. Standard errors are clustered by firm.

*, **, *** Denote statistical significance at 10 percent, 5 percent, and 1 percent levels, respectively (two-tailed tests). Robust T-statistics are shown in parentheses.

This table presents the results of the main tests from Table 3 to observe the variation between firm-years that had a new CEO and those that did not. The dependent variable in column (1) is the average sentence length of the risk factor disclosure, the dependent variable in column (2) is the number of unique words from LM Master dictionary used in the disclosure, and the dependent variable in column (3) is the Type Token Ratio of the risk factor disclosure. The main variable of interest is Liberal Court * CEO Change which is an interaction of Liberal court, our measure of litigation risk, and CEO Change, an indicator variable that takes value 1 for firm-years in which a new CEO was appointed. All tests include industry fixed effects and year fixed effects.

TABLE 10: ROBUSTNESS TESTS – USING STATE FIXED EFFECTS

$$RFD_complexity_{i,t} = \beta_0 + \beta_1 Liberal_court_{i,t} + \sum_{k=2}^{18} \beta_k Controls_{i,t} + FixedEffects + \varepsilon$$

VARIABLES	(1) Avg_ SentLength	(2) Unique_Vocab	(3) Type Token Ratio	(4) Avg_ SentLength	(5) Unique_Vocab	(6) Type Token Ratio
Liberal_Court	2.117*** [2.66]	173.499*** [8.20]	0.012*** [5.88]	1.984** [2.57]	160.721*** [7.77]	0.011*** [5.29]
Firm_Age	-0.005 [-0.91]	-0.684*** [-3.42]	-0.000*** [-3.72]	-0.003 [-0.41]	-0.836*** [-3.90]	-0.000*** [-3.95]
Avg_Accruals	0.032 [0.76]	3.701 [0.98]	0.000 [1.44]	-0.010 [-0.18]	0.825 [0.36]	0.000 [0.98]
BigN	0.238 [1.43]	11.577* [1.92]	0.001** [1.99]	0.203 [1.26]	11.228* [1.83]	0.001* [1.87]
BTM	-0.043* [-1.75]	2.135** [2.00]	0.000* [1.96]	-0.024 [-0.90]	2.119* [1.73]	0.000 [1.61]
Income	0.000 [0.31]	0.000 [0.21]	0.000 [0.80]	0.000 [0.31]	0.000 [0.05]	0.000 [0.66]
Leverage	0.813*** [2.75]	-5.058 [-0.70]	0.000 [0.07]	0.881*** [2.86]	-9.914 [-1.29]	-0.001 [-0.90]
Size	0.326*** [5.70]	4.933*** [3.41]	0.000** [2.52]	0.300*** [5.18]	3.161** [2.19]	0.000 [1.60]
Loss	0.386*** [3.15]	19.108*** [4.70]	0.002*** [4.00]	0.325*** [2.82]	14.216*** [4.01]	0.001*** [3.52]
Abn_Return	-0.442 [-0.66]	31.151 [1.60]	0.002 [1.32]	-0.612 [-0.93]	22.549 [1.22]	0.001 [0.79]
Stderet	19.105*** [5.11]	565.919*** [4.07]	0.055*** [3.73]	13.835*** [3.66]	336.083*** [2.76]	0.032** [2.56]
Beta	-0.295*** [-2.72]	6.030* [1.95]	0.001* [1.95]	-0.335*** [-3.05]	4.356 [1.27]	0.000 [1.06]
Returns Skewness	-0.023 [-1.49]	-1.361** [-2.35]	-0.000 [-1.36]	-0.023 [-1.34]	-1.115** [-2.02]	-0.000 [-1.03]
ROA	-0.091** [-2.05]	-3.368 [-0.97]	-0.000 [-0.93]	-0.041 [-0.69]	0.305 [0.13]	0.000 [0.04]
Sh_Turn	-0.063* [-1.65]	1.218 [0.58]	0.000 [0.83]	-0.045 [-1.23]	1.125 [0.55]	0.000 [0.65]
Ln_RFDLength	2.375*** [8.29]	614.057*** [47.19]	-0.078*** [-55.66]	2.307*** [7.21]	608.397*** [45.11]	-0.078*** [-53.12]
ZScore	0.000*** [10.28]	-0.011** [-2.38]	-0.000*** [-5.14]	0.000*** [6.10]	-0.013*** [-4.96]	-0.000*** [-8.60]
Lit_Risk KS	3.939 [1.47]	185.807** [2.19]	0.011 [1.27]	3.499 [1.30]	489.426*** [4.85]	0.037*** [3.72]
Constant	9.624*** [4.02]	-4,228.237*** [-37.57]	0.830*** [68.15]	10.594*** [3.95]	-4,156.221*** [-35.13]	0.836*** [63.95]
Observations	19,762	19,762	19,762	19,762	19,762	19,762
Adjusted R-squared	0.206	0.939	0.950	0.217	0.941	0.951
SIC2 FE	No	No	No	Yes	Yes	Yes
State FE	Yes	Yes	Yes	Yes	Yes	Yes
Year FE	Yes	Yes	Yes	Yes	Yes	Yes
Cluster	Firm	Firm	Firm	Firm	Firm	Firm

Notes: All variables are defined in Appendix A. Standard errors are clustered by firm.

*, **, *** Denote statistical significance at 10 percent, 5 percent, and 1 percent levels, respectively (two-tailed tests). Robust T-statistics are shown in parentheses.

This table presents the results of the main tests of risk factor disclosure complexity and litigation risk from Table 3, run with state fixed effects instead of industry fixed effects (Columns (1) to (3)), and tests run with state fixed effects, industry fixed effects, and year fixed effects (Columns (4) to (6)). The dependent variable in columns (1) and (4) is the average sentence length of the risk factor disclosure, the dependent variable in columns (2) and (5) is the number of unique words from LM Master dictionary used in the disclosure, and the dependent variable in columns (3) and (6) is the Type Token Ratio of the risk factor disclosure. The main variable of interest is *Liberal_court*, which is a proxy for litigation risk based on judge ideology.

TABLE 11: ROBUSTNESS TESTS – USING INDUSTRY DEMEANED DEPENDENT VARIABLES

$$Demeaned_RFD_complexity_{i,t} = \beta_0 + \beta_1 Liberal_court_{i,t} + \sum_{k=2}^{18} \beta_k Controls_{i,t} + StateFE + YearFE + \varepsilon$$

VARIABLES	(1)	(2)	(3)
	Industry demeaned		
	Avg_ SentLength	Unique_ Vocab	Type Token Ratio
Liberal_Court	1.707** [2.13]	107.368*** [3.51]	0.017*** [5.19]
Firm_Age	0.000 [0.05]	-0.094 [-0.31]	-0.000*** [-4.36]
Avg_Accruals	-0.080 [-0.83]	-13.715 [-1.53]	0.002 [1.39]
BigN	0.260 [1.53]	31.041*** [3.02]	-0.001 [-1.14]
BTM	-0.002 [-0.04]	8.978* [1.65]	-0.000 [-1.30]
Income	-0.000 [-0.02]	-0.004** [-2.30]	0.000 [1.54]
Leverage	0.874*** [2.95]	23.778 [1.61]	-0.003** [-2.23]
Size	0.267*** [4.71]	1.395 [0.50]	0.001** [1.99]
Loss	0.167 [1.34]	-19.786*** [-2.89]	0.005*** [6.55]
Abn_Return	-0.672 [-1.04]	1.701 [0.06]	0.004 [1.09]
Stderet	7.980** [2.22]	-816.619*** [-3.56]	0.163*** [5.78]
Beta	-0.237** [-2.19]	8.106 [1.41]	-0.001 [-0.83]
Returns Skewness	-0.020 [-1.28]	-1.139 [-1.13]	-0.000 [-0.62]
ROA	0.046 [0.51]	18.191** [2.21]	-0.002* [-1.71]
Sh_Turn	-0.002 [-0.05]	10.633*** [4.15]	-0.001* [-1.78]
Ln_RFDLength	1.924*** [6.84]	521.499*** [42.41]	-0.068*** [-39.01]
ZScore	0.000*** [3.41]	-0.017** [-2.01]	-0.000 [-0.74]
Lit_Risk KS	0.816 [0.30]	-275.604* [-1.77]	0.084*** [4.88]
Constant	-19.833*** [-8.46]	-4,637.988*** [-43.50]	0.580*** [38.13]
Observations	19,762	19,762	19,762
Adjusted R-squared	0.143	0.785	0.798
State FE	Yes	Yes	Yes
Year FE	Yes	Yes	Yes
Cluster	Firm	Firm	Firm

Notes: All variables are defined in Appendix A. Standard errors are clustered by firm.

*, **, *** Denote statistical significance at 10 percent, 5 percent, and 1 percent levels, respectively (two-tailed tests). Robust T-statistics are shown in parentheses.

This table presents the results of the main tests of risk factor disclosure complexity and litigation risk from Table 3, run with dependent variables from which industry level average has been subtracted. The dependent variable in columns (1) and (2) is the industry demeaned average sentence length of the risk factor disclosure, the dependent variable in columns (3) and (4) is the industry demeaned number of unique words from LM Master dictionary used in the disclosure, and the dependent variable in columns (5) and (6) is the industry demeaned Type Token Ratio of the risk factor disclosure. The main variable of interest is *Liberal_court*, which is a proxy for litigation risk based on judge ideology. All odd-numbered columns are run using industry level and firm level fixed effects, and all even-numbered columns are run using state level and year level fixed effects.